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T-cell immunoglobulin and mucin 3 protein (Tim-3) is a type-I transmembrane protein known to 
negatively regulate Th1 and Th17 CD4 T cells, and CD8 T cell mediated immune responses. 
Tim-3 expression level correlates with the severity of T cell exhaustion under conditions of 
chronic viral infection and tumor burden and Tim-3 antibodies can reverse this dysfunctional 
phenotype. Exploring the signal transduction mechanism of Tim-3, I demonstrated that ectopic 
expression of Tim-3 enhanced NFAT/AP-1, NFAT and NF-κB reporter activity induced by TCR 
stimulation, and enhanced AP-1 reporter activity independent of TCR stimulation. Two tyrosines 
in the cytosolic tail of Tim-3 are responsible for the potentiation of signal transduction by TCR 
in a redundant manner. I demonstrated that the Src family kinase (SFK) Fyn can phosphorylate 
Y256 and Y263 residues of Tim-3. An SH2 domain screen and co-immunoprecipitation 
identified p85 PI3K interaction with Tim-3 in a tyrosine phosphorylation-dependent manner. I 
also found that Tim-3 expression upregulates phosphorylation of PLC-γ1 and MAP kinases 
ERK1/2, p38, and JNK. Finally, I demonstrated that Tim-3 upregulates phosphorylation of 
ribosomal protein S6, a downstream target of PI3K and ERK, and IL-2 secretion induced by 
TCR stimulation. I conclude that potentiation of NFAT/AP1 and NF-κB activity by Tim-3 is 
mediated by enhancement of the PI3K, PLC-γ1 and ERK pathways. Thus, we have demonstrated 
a paradoxical activating function of Tim-3 in TCR signaling, while Tim-3 is known as a negative 
regulator of Th1 and Tc1 T cell mediated immune responses. This augmentation of TCR 
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signaling by Tim-3 may contribute to driving and/or maintaining T cell exhaustion. 
Alternatively, Tim-3 may have a dual activation and inhibition role depending on the ligands 
available at a particular stage of T cell activation. 
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1.0  INTRODUCTION 
1.1 TIM FAMILY 
There are 8 TIM family genes identified in mouse, which are clustered in chromosome 11, and 
there are 3 TIM family genes in human, in 5q33. Murine Tim-1, Tim-2, Tim-3 and Tim-4 encode 
functional proteins, but Tims-5 to 8 are predicted genes. Sequences of murine Tim-1 and 2 are 
homologous to human TIM-1, and sequences of murine Tim-3 and 4 are homologous to their 
corresponding human TIM-3 and 4. All TIM family genes encode type I transmembrane 
glycoproteins which consist of an IgV domain, a mucin domain, transmembrane domain and a 
cytosolic tail. The cytosolic tails of murine Tim-1, 2 and Tim-3 have putative tyrosine 
phosphorylation sites, possibly mediating signal transduction, but the cytosolic tail of Tim-4 does 
not [1, 2]. Since the first gene of Tim family has been identified as a hepatitis A virus cellular 
receptor [3], regulatory roles of Tim family in immune conditions such as autoimmune disease, 
allergy, and infection and cancer have been reported. 
1.1.1 Tim-1 
Tim-1 was discovered and cloned as a hepatitis A virus cellular receptor (HAVCR) in African 
green monkey kidney cells and in human organs including liver and kidney [3, 4]. Another group 
identified Tim-1 as kidney injury molecule 1 (KIM-1), which was upregulated after ischemic 
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injury in damaged and regenerating proximal tubule epithelial cells [5]. Soluble KIM-1/Tim-1 is 
used as a urinary biomarker for acute tubule necrosis. Since it was shown that Tim-1 blockade 
(with mAb RMT1-10) was protective against renal ischemia-reperfusion injury, decreasing 
infiltration of immune cells and production of cytokines, Tim-1 was suggested as a therapeutic 
target, not only a biomarker, for renal injury [6].  
An immunoregulatory role of Tim-1 was first suggested by a study showing the genetic 
relationship between Tim-1 and airway hyperreactivity. In an attempt to identify the locus 
responsible for the reduced airway hyperreactivity phenotype in HBA (DBA/2) mice, positional 
cloning identified a locus named Tapr (T cell and airway phenotype regulator) on chromosome 
11. The locus was associated with Th2 cytokine production, which was genetically separable 
from IL-4 cytokine gene cluster and other nearby cytokine genes. Within the locus, Tim family 
genes were found. In addition, major polymorphisms in Tim-1 and Tim-3 were found [7].  
Tim-4 and phosphatidylserine (PS) were identified as natural ligands of Tim-1. Tim-4, 
which is expressed in APC but not in T cells, interacts with both the IgV and mucin domains of 
Tim-1, and the Tim-1/Tim-4-Ig interaction induces hyperproliferation of T cells [8].  Both Tim-1 
and Tim-4 interact with PS, which is mediated by the metal ion dependent ligand binding site 
(MILIBS), and Tim-1 and Tim-4 play roles in phagocytosis of apoptotic cells and exosomes [9-
11]. Tim-1 also can form a homodimer with another Tim-1 molecule expressed on a neighboring 
cell surface (in trans).  
In T cells, Tim-1 is predominantly expressed in Th2 cells as compared to Th1 cells [12], 
and functions as co-stimulator for T cell activation induced by TCR stimulation. Transient 
overexpression of Tim-1, or its crosslinking with agonistic antibody or with recombinant Tim-4, 
upregulate T cell proliferation and Th2 cytokine production [8, 13]. Tim-1 is constitutively 
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expressed in bone marrow-derived mast cell (BMMC) and anti-Tim-1 antibodies (3B3, RMT1-4, 
and RTM1-17) and recombinant Tim-4 enhance Th2 cytokine (IL-4, 6, and 13) production in 
IgE-sensitized BMMC [14].  B cells express both Tim-1 and Tim-1L, Tim-1 expression is 
upregulated by stimulation with IgM and anti-CD40, but not LPS, while Tim-1L expression in B 
cells is constitutive, according to the staining with anti-Tim-1 antibody and Tim-1-Ig binding. 
Anti-Tim-1 antibody (RMT1-17) treatment of B cells stimulated with IgM and anti-CD40 
enhances proliferation and differentiation to plasma cells, and as a consequence, antibody 
production is increased [15].   
Xiao et al. generated Tim-1
Δmucin
 mice and demonstrated the role of Tim-1 in 
development of regulatory B cells. The number of FoxP3
+
 regulatory T cells and IL-10 
production in CD4 T were normal in the mutant mice. In wild type mice, the frequency of IL-10 
producing B cells increased as the mice aged (< 6 months vs. >10 months). Moreover in a 
comparison of young WT mice and Tim-1
Δmucin
 mice, the frequency of IL-10 producing B cells 
was lower in Tim-1
Δmucin
 mice. In addition, in Tim-1
Δmucin
 mice, the number of IL-10-producing 
B cells minimally increased as they aged over 10 months [16]. These data suggest that Tim-1 
functions as a stimulatory molecule in B cells, but is also required for development of regulatory 
B cells.  
de Souza et al. revealed that Tim-1 functions as a co-stimulatory molecule and began to 
define its signaling mechanism in T cells. Ectopic expression of Tim-1 upregulated NFAT/AP-1 
reporter activation induced by TCR/CD28, but not NF-κB reporter stimulation, in which Y256 
was responsible for this Tim-1 function[13]. According to an SH2 domain array, the 
phosphotyrosine residue in Tim-1 cytosolic tail interacts with p85, Fyn, and tentatively other 
molecules with SH2 domains [17].  
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1.1.2 Tim-2 
Tim-2 is a member of Tim family protein which is also homologous to human TIM-1. Similar to 
Tim-1, Tim-2 is expressed preferentially on Th2 T cells, but Tim-2 expression was not detectable 
on B cells, macrophages, and dendritic cells [18]. Tim-2 functions as an inhibitory molecule for 
Th2 immune responses. In vivo administration of Tim-2-Ig, to block the Tim-2/Tim-2L 
interaction, led to increased production of Th2 cytokines IL-4 and IL-10. In a Th1 type EAE 
mouse model, Tim-2 blockade delayed the onset of disease and ameliorated its severity, 
suggesting that Tim-2 negatively regulates Th2 cells and shifts the balance between Th1 and Th2 
immune responses [18]. Consistently, Tim-2 deficient mice displayed exacerbation of lung 
inflammation in a Th2 type airway atopic response model [19].  
On the contrary, Tim-2 ligand Sema4A, which is expressed by dendritic cells and B cells, 
upregulated CD4 T cell proliferation and activation.  Sema4A-Fc treatment enhanced production 
of IFN-γ and IL-4 under Th1 and Th2 polarization conditions, respectively, in vitro. In an EAE 
model, blockade of Sema4A enhanced CD4 T cell proliferation and production of IFN-γ and IL-
4, and suppressed the development of EAE [20]. It is possible that Tim-2 and Sema4A might 
have other partners and the effect of blockade of Sema4A is not equivalent to blockade of Tim-2.  
The investigation on Tim-2 signal transduction revealed that ectopic expression of Tim-2 
in Jurkat T cells suppresses calcium mobilization and ERK activation, leading to inhibition of 
activation of NFAT/AP-1 transcription factor [21]. Tim-2 in can homo-dimerize via its IgV 
domain (in cis) and the Tim-2 dimerization prevents the in trans-homophilic interaction of Tim-1 
[11]. Therefore, Tim-2 may inhibit the co-stimulatory function of Th1 in an extrinsic manner as 
well. It has been found that Tim-2 in oligodendrocytes recognizes H-ferritin and facilitates iron 
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transfer, but whether the Tim-2/H-ferritin axis has a role in the immune system has not been 
determined yet.  
1.1.3 Tim-4 
Tim-4 is expressed on APCs, including CD11c
+
 dendritic cells, stromal cells, CD19
-
CD11b
+
 
macrophages, CD19
+
CD11b
+
B cells, but not in in CD19
+
CD11b
-
 conventional B cells [8, 22-24]. 
To date, two known major functions of Tim-4 are to activate Th2 cells as a Tim-1 ligand and to 
mediate phagocytosis of apoptotic cells and exosomes as a PS receptor. Tim-1/Tim-4-Ig ligation 
regulates T cell activation and Th2 mediated immune responses. Conjugation of Tim-1 by Tim-
4-Ig induces proliferation of T cells and phosphorylation of LAT, Akt and ERK, and expansion 
of CD3
+
 T cells [8, 25]. A significant role for Tim-4 signaling in activation of Th2 type immune 
responses and development of intestinal food allergy was shown [24].  
These studies demonstrated the activating function of Tim-4 as a ligand of Tim-1. However, the 
Tim-4 signal via Tim-1 was inhibitory in naïve and pre-activated T cells, suggesting that Tim-
1/Tim-4 signaling has a bimodal function depending the stage of T call activation [26].  
Tim-4 recognizes PS exposed on apoptotic cells and exosomes, to mediate the 
engulfment by phagocytic cells [9, 10, 27]. Recent studies suggested that the Tim-4-mediated 
removal of apoptotic bodies has implications for autoimmunity and tolerance. Tim-4 deficiency 
in mice resulted in hyperactivation of T cells and B cells, and elevated serum immunoglobulins 
and autoantibodies to dsDNA [22]. It has been shown that clearance of antigen-specific T cells, 
mediated by Tim-4 expressing medullary macrophages, is involved in respiratory tolerance [28]. 
Genetic studies in a Chinese Han population found an association of TIM-4 polymorphisms with 
asthma and rheumatoid arthritis [29-31].  
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Unlike other Tim family proteins Tim-4 does not have a putative tyrosine 
phosphorylation site in its cytosolic tail, and the transmembrane and the cytosolic domains of 
Tim-4 were dispensable for phagocytosis of apoptotic cells. Therefore Tim-4 may serve as a 
binding receptor and a ligand for Tim-1, rather than a signaling receptor [32].  
1.2 TIM-3 GENE (HAVCR2) 
The gene encoding Tim-3 (Havcr2) was found within the Tapr locus of HBA mice, along with 
the genes encoding Tim-1 and Tim-4. Mouse Tim-3 gene contains seven exons [7], with 
segmentation of functional domain of the protein roughly equivalent to segmentation of the 
exons. The signal peptide sequence is encoded by exon 1, and the IgV domain is encoded by 
exon 2. The mucin and transmembrane domains are encoded by exons 3 to 5, and the cytosolic 
domain is encoded by exons 6 and 7 (Figure 1). Polymorphisms in seven amino acid residues 
between BALB/c and HBA mice were found, which are clustered in the IgV domain [7]. 
Polymorphisms in the BC loop of the IgV domain led to the loss of a potential O-linked 
glycosylation site in the HBA allele of Tim-3, which might affect binding of Tim-3 to its 
ligand(s).  
Tim-3 gene also encodes a shorter isoform of Tim-3, which is generated by alternative 
splicing [33]. This shorter form of Tim-3 lacks exon 3, 4 and 5 and, as a consequence, lacks the 
mucin and transmembrane domains [33]. Expression of a soluble form of Tim-3 (sTim-3) was 
detectable in splenocytes, but not in non-lymphoid organs, and stimulation with HSP70-peptide 
complex induced the upregulation of sTim-3 expression in splenocytes.  Several previous studies 
demonstrated that Tim-3-Ig fusion protein blocked the inhibitory function of Tim-3 [33, 34]. By 
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contrast, sTim-3 inhibited T cell mediated immune responses [35]. However, which cells express 
sTim-3, and the mechanisms by which sTim-3 and sTim-3-Ig differently regulate Tim-3, are not 
known. The involvement of Tim-3 polymorphisms in human immune-related diseases includes 
asthma, atopic dermatitis, and rheumatoid arthritis [36-40]. Several known polymorphisms are 
depicted in Figure 1 and more details will be discussed in the later part of this chapter (1.6.2 and 
1.6.3).  
1.3 TIM-3 STRUCTURE 
Similar to other Tim family members, Tim-3 is a type I transmembrane protein. The extracellular 
domain of Tim-3 consists of IgV and mucin domains. The cytosolic tail of Tim-3 contains six 
tyrosine residues, four of which are predicted phosphorylation sites. The extracellular domain of 
Tim-3 has multiple putative N- and O-glycosylation motifs. Among them, there are two N-
glycosylation sites and one O-glycosylation site in the IgV domain (no O-glycosylation motif in 
HBA), which potentially serve as galectin-9 binding sites. The Tim-3 IgV domain consists of 
two sheets formed by A,C,C’,C”,F and G β-strands and by B, E and D β-strands, with the two 
sheets facing each other like a sandwich. The main structure of the IgV domain is stabilized by a 
disulfide bond tethering B and F strands (Cys38-Cys111) and two hydrogen bonds (Trp52-Val94, 
and Tyr109-Asp105), which are common features in Ig superfamily proteins. Two disulfide 
bonds (Cys52-Cys63 and Cys58-Cys100) hold the CC’ loop to C and C’ β-sheet, shaping the 
cleft lined by CC’ and FG loop. The CC’ and FG loops form a narrow pocket in the IgV domain.  
Since potential glycosylation sites (T44, N74, N100) (Figure 2, blue and red, Figure 3, 
blue) are located distantly from the pocket, Cao et al. proposed the pocket as a non-galectin-9 
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ligand binding site [41]. The pocket surrounded by CC’-FG loops, conserved in Tim-1 and Tim-
4, interacts with PS in coordination with metal ion, and has been termed the metal ion-dependent 
ligand binding site (MILIBS) [11, 42]. DeKruyff et al. determined the structure of PS bound to 
the MILIBS (Figure 3, magenta and black) from the Tim-3 IgV domain, in coordination with a 
calcium ion. There are seven polymorphic amino acid differences between BALB/c and HBA, 
four of them clustered in the A’ stand (HBA1) and four clustered in the BC loop (HBA2) (Figure 
2 and Figure 3 green).  
The BALB/c IgV domain interacts more avidly with PS in liposomes than does the HBA 
allele. Introduction of polymorphisms in the BC loop (HBA2) to BALB/c IgV reduced the 
binding affinity as low as that of HBA IgV, and point mutation of R22A in Tim-3 IgV and R25A 
in Tim-4 IgV domain decreased the binding affinity to PS. Although R22 does not reside in the 
MILIBS, R22 in the BC loop mediates electrostatic interactions with the charged phosphate head 
of membrane phospholipids [43].  
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Figure 1. Schematic figure of Tim-3 gene and polymorphisms 
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Figure 2. Amino acid sequence of BALB/c and HBA Tim-3h 
Amino acid sequence of BALB/c and HBA Tim-3 is aligned by ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). O-and N-glycosylation sites are predicted with NetOGlyc and 
NetNGlyc program (http://www.cbs.dtu.dk/services/NetOGlyc/, http://www.cbs.dtu.dk/services/NetNGlyc/). 
Polymorphisms and glycosylation sites are highlighted as indicated, and β-strands are shown with lines over the 
corresponding sequences. 
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Figure 3. Tim-3 IgV domain structure 
Non-galectin-9 ligand binding residues (red), MILIBS residues engaged metal ion coordination (black), hydrophobic 
residues in the tip of FG and CC’ loop (magenta), glycosylation site (blue), polymorphisms (green) Tim-3 
expression and function. Diagrams were generated using PDB ID: 2OYP using the PyMol software. 
 12 
1.4 TIM-3 EXPRESSION AND FUNCTIONS 
1.4.1 T cells 
Tim-3 is expressed on activated Th1 cells, but not Th2 cells [44]. Blocking Tim-3/Tim-3L 
interaction, using blocking antibody or Tim-3 Ig fusion proteins, induced hyperproliferation and 
increases in Th1 cytokine secretion in T cells during development of autoimmunity and allograft 
rejection. Therefore, the concept is widely accepted that Tim-3 is an inhibitory regulator in Th1 
immunity [33, 34, 44]. Although lower than in Th1 cells, Tim-3 is expressed in activated Th17 
cells. When human primary CD4 T cells were stimulated with anti-CD3/CD28 antibodies, 
addition of Tim-3 “antagonistic” antibody enhanced the secretion of IFN-γ, IL-12, and IL-17 and 
IL-6, but not of Th2 cytokines.  In psoriasis, a Th1- and Th17-mediated autoimmune disease of 
the skin, induction of Tim-3 expression in Th1, Th17 and Tc1 cells upon activation was less 
efficient in patients than in healthy donors [45]. Soluble galectin-9 treatment reduced the number 
of IFN-γ and IL-17 producing T cells, and mitigated the skin inflammation and thickness [46].  
When strong antigen stimulation persists for a long period, as in chronic infection or 
tumors, Tim-3 expression is upregulated on CD8 T cells over time along with other inhibitory 
receptors, such as PD-1. This appears to cause virus/tumor-specific CD8 T cells to undergo a 
gradual loss of function, called exhaustion. Tim-3 and PD-1 double positive cells displayed more 
severe dysfunctional phenotype than Tim-3 or PD-1 single positive cells. Consistently, blocking 
Tim-3 and PD-1 restore CD8 T cell functions more efficiently than single blockade of Tim-3 or 
PD-1 [47-49], suggesting that Tim-3 and PD-1 are involved in induction of CD8 T cell 
exhaustion, cooperatively.  
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Tim-3 expressing CD4
+
FoxP3
+
 regulatory T cells were found in tumor tissues, and 
allograft tissues, and HCV infected patients. Among the tumor infiltrating T cells (TILs) in non-
small cell lung cancer (NSCLC), 70% of TIM-3
+
CD4
+
 T cells are FoxP3
+
 and 60% of FoxP3
+
 
TILs are Tim-3+ [50]. Among allograft infiltrating T cells, CD4
+
FoxP3
+
Tim-3
+
 T cells express 
more CTLA-4, IL-10 and TGF-β and are more potent in suppression of effector T cells than 
CD4
+
FoxP3
+
Tim-3
-
 T cells. However, possibly due to the expression of Tim-3, Tim-3
+
 
regulatory T cells were more prone to apoptosis induced by galectin-9 [51]. In HCV infection, 
Tim-3/galectin-9 seems to be involved in development and proliferation of regulatory T cells. Ji 
et al. showed that galectin-9 induces development of regulatory T cells from activated CD4 T 
cells, and Moorman et al. showed a positive correlation between Tim-3 expression and 
regulatory T cell proliferation. FoxP3
+
 regulatory T cells are less susceptible to activation-
induced cell death in a Tim-3 dependent manner than FoxP3
-
 effector T cells. These results 
suggest that Tim-3 signaling is suppressive to the effector T cell, but favors function and/or 
survival of regulatory T cells.  
1.4.2 Mast cells 
Tim-3 is constitutively expressed on mouse peritoneal mast cells, and bone marrow derived 
cultured mast cells (BMMC), and expression was increased after IgE and antigen stimulation. 
[14, 52]. Treatment with polyclonal Tim-3 antibody upregulated the IL-4, IL-6, and IL-13 
production and inhibited IL-3 withdrawal-induced apoptosis in BMMC sensitized with IgE and 
antigen. However, the same  polyclonal Tim-3 antibody did not influence mast cell degranulation 
or activation of ERK and JNK MAP kinases [14].  
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1.4.3 NK cells 
Tim-3 is expressed heterogeneously on immature CD56
bright
CD16
-
 NK cell subsets, and is 
expressed in all human CD56
dim
CD16+NK cell subsets in blood from healthy donors, Therefore 
Tim-3 was proposed as a marker for mature NK cells [53]. Elevated expression of Tim-3 was 
found in hepatitis B virus (HBV) infected patients, and atherosclerosis patients. Blockade of 
Tim-3 enhanced IFN-γ production and cytotoxicity of NK cells from HBV patients [54] and 
there was an inverse correlation between Tim-3 expression and number of peripheral NK cells 
[55]. Analysis of NK cells from healthy donors demonstrated that Tim-3 expressing cells were 
normal in cytokine production and cytotoxic function, but these responses were inhibited by 
cross-linking of Tim-3 [53]. According to these studies, Tim-3 is an inhibitory receptor on NK 
cells, nonetheless, there is a contradictory report as well. Thus, overexpression of Tim-3 on NK 
cell lines showed increase in IFN-γ production, while Tim-3 blockade decreased IFN-γ 
production [56]. 
1.4.4 Dendritic cells, macrophages, and monocytes. 
Tim-3 is expressed by many subsets of dendritic cells, macrophages, and monocytes. Anderson 
et al. first demonstrated that Tim-3 enhances TNF-α production in innate immune cells, and 
differentially activates signaling in dendritic cells and Th1 cells, supporting the concept that 
Tim-3 plays negative or positive roles in adaptive and innate immunity respectively [57]. 
However, recent studies showed that Tim-3 also has an inhibitory role in innate immune cells. 
Thus, Tim-3 is constitutively expressed by resting human CD14
+
monocyte/macrophage, and 
Tim-3 expression was downregulated upon TLR stimulation [58, 59]. There was an inverse 
 15 
correlation between Tim-3 expression and IL-12 production, and antibody blockade of Tim-3 
signaling upregulated TLR-mediated IL-12 production [58, 59]. Tim-3 expressed on 
macrophages, monocytes, and splenic dendritic cells recognizes phsophatidylserine exposed on 
the cell surface and mediates the engulfment of apoptotic cells. This Tim-3 mediated 
phagocytosis is involved in cross-presentation of antigens from the apoptotic cells. Apparently, 
via a similar mechanism, Tim-3 expressing macrophages and dendritic cells contribute to 
fetomaternal tolerance. This Tim-3 blockade results in accumulation of apoptotic bodies, 
inflammatory granulocytes and macrophages at the uteroplacental interface [60].  
1.5 TIM-3 LIGANDS 
1.5.1 Galectin-9 
Galectins are soluble β-galactoside-binding lectins, preferably binding to N-acetyllactosamine 
and polylactosamine chain. Galectins are evolutionally conserved in animals and widely 
distributed. Galectins can be classified into three types, based on their structure. Prototypic 
galectins (Galectin-1,-2-,-5,-7,-13,-14,-15) contain a single conserved carbohydrate recognition 
domain (CRD) and form dimers. Tandem repeat galectins (galectin-4,-6,-8,-9-,-12) consist of 
two CRD domains separated by a linker domain. Galectin-3 is the only chimeric galectin, which 
consists of one CRD domain in the C-terminus linked with proline and glycine rich tandem 
repeats in the N-terminus [61].  
Galectins are known to play roles in the regulation of many parts of the immune response. 
Galectins are synthesized in the cytosol and secreted by an unknown mechanism despite having 
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no classical signal peptide sequence for targeting to the ER. The secreted galectins bind to 
multivalent glycan ligands on the cell surface or extracellular matrix to form lattices. The 
galectin-glycoproetin lattices can control TCR signaling, cytokine signaling, metabolism, and 
apoptosis by reorganizing membrane microdomains and localization of glycoproteins in the 
membrane and suppressing endocytosis [62, 63]. Found in the cytosol and nucleus, galectins can 
bind to intracellular ligands to participate in intracellular processes, including signal transduction, 
trafficking, apoptosis and mRNA splicing [64-66].   
Zhu et al first identified galectin-9 as a ligand of Tim-3, binding to carbohydrate chains in 
Tim-3 and mediating an immune regulatory role in a Th1 cell mediated autoimmune condition 
[67].  In vitro galectin-9 enhanced calcium flux and cell death in Th1 cells, which was partially 
dependent on Tim-3. In vivo administration of galectin-9 led to elimination of myelin 
oligodendrocyte glycoprotein (MOG) peptide (MOG 35-55) specific IFN-γ producing Th1 cells 
in an EAE model, and ameliorated the severity of the disease [67]. However, galectin-9 can 
regulate T cell function in autoimmune conditions through both Tim-3-dependent and –
independent effects. In EAE and collagen-induced arthritis (CIA) models, galectin-9 treatment 
reduced the number of Tim-3
+
CD4 Th1 cells and Th17 cells, but also suppressed Th17 
differentiation by inducing differentiation of regulatory T cells, in a Tim-3 independent manner 
[68, 69]. In NOD model of diabetes, galectin-9 binds to CD40 expressed on CD4
lo
CD40
+
T cells 
to prevent proliferation and to induce cell death, Tim-3 independently[70].   
Galectin-9 also has implication in infectious diseases. Thus, galectin-9 has a suppressive 
role in CD8 and Th17 T cell responses against infection by HSV [71], influenza A virus [72], 
HBV [73], HCV [74] and Klebsiella pneumoniae [75].  The role of galectin-9 in tumor biology is 
not linear, but more complex. Galectin-9 has an anti-tumor function by inducing apoptosis of 
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tumor cells [76-80] and preventing metastasis [81-84]. However, in the regulation of tumor 
immunity, galectin-9 has both activating and suppressive roles. In general, it seems that galectin-
9 negatively influences anti-tumor T cell responses. Galectin-9 induces apoptosis of CD4 and 
CD8 T cells [85-87] and inhibits anti-tumor function of T cells [87-89]. On the other hand, there 
are reports that galectin-9 administration induces expansion of plasmacytoid DC-like 
macrophages, by which NK cells or CD8 T cells are activated and prolong the survival of tumor 
bearing mice  [56, 90-92]. Galectin-9 can mediate both positive and negative role in T cell 
immunity. Independently of Tim-3, galectin-9 could induce apoptosis and inhibit proliferation at 
higher doses and induced pro-inflammatory cytokine production and proliferation at lower doses 
[70, 93].  
1.5.2 Phosphatidylserine (PS) 
PS is a glycolipid that comprises 3-10% of total membrane lipids and consists of a glycerol 
backbone esterified with two acyl chains at sn-1 and sn-2 positions and a polar head group 
attached to the sn-3 position [94].  PS is found exclusively on the inner leaflet of the cell 
membrane, which is actively maintained by an ATP-dependent amino phospholipid lipase, and 
exposed on outer leaflet of the apoptotic cells providing an ‘eat me’ signal for phagocytic cells 
[95].  It was shown that Tim-1 and Tim-4 are receptors for PS, which facilitates engulfment of 
apoptotic cells to help prevent autoimmunity and for the recognition of exosomes involved in 
intercellular signaling [9, 10, 96].   
Crystallography studies of the PS/Tim-4 IgV domain complex revealed that PS binds to 
metal ion-dependent ligand binding site (MILIB) built by the CC’ and FG loops of Tim-4 IgV 
domain, which are conserved in Tim-1 and Tim-3 as well. A crystal structure of the PS/Tim-3 
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IgV domain complex revealed that PS bound to the MILIBS in coordination with calcium. 
Mutation of either amino acid residues interacting with PS or the metal ion resulted in a large 
decrease in the affinity of the Tim-3 IgV domain for PS [43]. Although the affinity of PS to Tim-
3 was much lower than affinity to Tim-1 and Tim-4, Tim-3 is crucial for the clearance of 
apoptotic cells and cross-presentation of dying cell-associated antigens [97].  
1.5.3  HMGB1 
HMGB1 (high mobility group protein B1) is a nuclear protein with two DNA binding motifs. 
Intracelluarly, HMGB1 regulates DNA repair, V(D)J recombination, transcription and 
organization of DNA structure [98-100].  When released to the extracellular space, HMGB1 
functions as a pro-inflammatory molecule. HMBGB1 binds to RAGE by itself to induce 
chemotaxis and proliferation, and also forms complexes with IL-1, nucleosome, and LPS to 
induce stronger inflammatory responses initiated by IL-1R and surface TLRs [101]. Extracellular 
HMGB1-nucleic acid complex activates endosomal TLR3, 7 and 9, suggesting that HMGB1 
plays a role in delivery of extracellular nucleic acids into the cytosol [102, 103].   
Recently, Tim-3 was found as a receptor of HMGB1. Chiba et al. demonstrated that Tim-
3 bound HMGB1 and the interaction is abrogated by single amino acid mutation near the FG 
loop of Tim-3 IgV domain that forms the metal-ion dependent ligand binding site (MILIBS). 
Tim-3 binds to the A-Box of HMGB1 to compete with B-DNA for binding to HMGB1, by 
which Tim-3 may inhibit the delivery of nucleic acids to endosomes, and suppress innate 
immune responses mediated by nucleic acids in DC. In this study, it was not directly tested 
whether PS and HMGB1 compete for binding to Tim-3 IgV domain, although AnnexinV 
treatment did not alter the Tim-3 dependent inhibition of nucleic acid-mediated IFN-β1 
 19 
production [104]. Thus, HMGB1 may bind to a motif on Tim-3 different from where PS binds. 
Although point mutation of an amino acid residue on the tip of FG loop of the Tim-3 IgV domain 
impaired the interaction with HMGB1, it may be because of more severe disruption in the IgV 
structure. 
1.5.4 Unknown ligand 
When the crystal structure of the Tim-3 IgV domain and the existence of a non-galectin-9 ligand 
were reported by Cao et al, a cleft lined with CC’ and FG loops drew attention as a novel ligand 
binding site. Later studies demonstrated that PS and HMGB1 interact with the IgV domain of 
Tim-3, and the interaction was abrogated when residues near the cleft were mutated. Yet it is not 
clear whether the unknown ligand described in Cao’s study was PS or HMGB1. In Cao’s study 
Tim-3 IgV tetramer bound to almost all CD4 and CD8 T cell, and macrophages, while in 
DeKruyff’s study, Tim-3 transfected cells specifically bound to apoptotic thymocytes but, not to 
live thymocytes. Although, in these studies, expression of putative Tim-3 ligands was analyzed 
using different reagents (Tim-3 IgV tetramer vs. Tim-3 expressing cells), surface 
expression/exposure profiles of the ligands between the two studies seemed different from each 
other.  HMGB1 exists as an intracellular or secreted protein, but not as a membrane-bound 
protein, and LPS treatment induces HMGB1 release in macrophage [105]. However, LPS and 
IFN-γ treatment did not affect Tim-3 IgV tetramer binding to the surface of macrophage 
according to Cao’s study [41]. Given all those finding, there is the possibility that another 
unknown ligand of Tim-3 exists still. 
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1.6 TIM-3 FUNCTION  
1.6.1 Multiple sclerosis/EAE 
The function of Tim-3 in regulation of immune responses was first described in EAE, a mouse 
model for multiple sclerosis (MS).  Tim-3 was expressed in active Th1 T cells but not in Th2 
cells, after in vitro polarization. During development of EAE in SJL mice by immunization with 
myelin proteolipid protein (PLP) peptide, Tim-3 expression was upregulated on CD4 and CD8 T 
cells and at low levels on CD11b
+
 cells. The upregulation of Tim-3 expression in lymph nodes 
preceded the disease onset and Tim-3 expression in the brain peaked at disease onset. Then Tim-
3 expression in both lymph node and brain was downregulated to near basal levels at the 
maximal disease score. Treatment with blocking anti-Tim-3 mAb exacerbated disease severity 
and mortality inducing proliferation and activation of CD11b
+
/F4/80
+
 macrophages in vivo. 
Treatment of EAE induced mice with galectin-9, a Tim-3 ligand, induced Th1 cell death in vivo, 
including  IFN-γ producing MOG peptide-specific T cells, and ameliorated EAE symptoms[67].   
Not only in the mouse model, but also in human MS, the role of Tim-3 was examined. T 
cell clones isolated from cerebrospinal fluid (CSF) of MS patients expressed less Tim-3 and 
produced more IFN-γ. Functionally, the clones from MS patients were more resistant to the 
tolerance induction by CD28 blockade during TCR stimulation. In addition to the inverse 
correlation between Tim-3 expression and cytokine production in T cells, more direct evidence 
of the suppressive role of Tim-3 in T cell function was revealed. When Tim-3 expression in 
human T cells was reduced by siRNA, proliferation and IFN-γ production were enhanced in CD4 
T cells [106]. The CD4 T cells from PMBCs of healthy control and MS patient responded 
differently to Tim-3 blockade. Tim-3 antibody treatment augmented IFN-γ production in CD4 T 
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cells from healthy controls upon TCR stimulation, while IFN-γ production in CD4 T cells from 
untreated MS patients was not affected. In contrast to the untreated MS patients,  T cells from 
treated MS patients were responsive to TIM-3 blockade, in which restoration of TIM-3 
expression was found [107]. Therefore, the loss of immunoregulation by TIM-3 was suggested 
as a contributing factor to the development of multiple sclerosis.  
1.6.2 Rheumatioid arthritis (RA) 
Since rheumatoid arthritis (RA) is thought to be a Th1-and Th17-mediated autoimmune disease, 
the protective role of Tim-3 in rheumatoid arthritis is expected. Galectin-9 deficient C57BL/6J 
mice are susceptible to bovine type II collagen (BCII) induced collagen-induced arthritis (CIA), 
while wild type C57BL/6J mice is resistant to CIA. Administration of galectin-9 reduced the  
clinical score and the symptoms of CIA in a dose dependent manner, lowering the level of pro-
inflammatory cytokines (IL-1β, IL-6, MCP-1, and MIP-2) and Th1 and Th17 cytokines  (IL-12, 
IFN-γ, and IL-17) in joints  and eliminating Tim-3+CXCR3+CD4+ Th1 and Th17 T cells, but not 
CCR4
+
T1ST2
+
CD4 Th2 T cells. Moreover, galectin-9 induced the differentiation of regulatory T 
cells but repressed differentiation of Th17 cells [68].  
In human samples, there was an inverse correlation between Tim-3 expression and joint 
disease activity score in RA patients [108]. Tim-3 expression and susceptibility to galecitn-9 
induced apoptosis was lower in the CD4 T cells isolated from RA patients, compared to CD4 T 
cells from healthy controls, suggesting that loss of negative regulation in Th1 cells in RA 
patients contributes to the disease development [109]. Two genetic studies of Korean RA 
patients showed that the polymorphisms -574G>T, 4259T>G, rs35960726 were associated with 
RA [40, 110]. Another study in a Chinese population suggested that the 4259G>T polymorphism 
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is associated with RA in both Hui and Han populations while -1541C>T or -574T>G were 
associated Hui and Han population respectively [111]. 
1.6.3 Allergic diseases 
Tim-3 is preferentially expressed in Th1 cells, versus Th2 cells, and is known to negatively 
regulate Th1T cell responses. However, Tim-3 may also be able to affect Th2-driven allergic 
diseases by indirectly modulating the balance between Th1 and Th2 type responses. 
Administration of anti-Tim-3 antibody decreased the production of Th2 cytokines and infiltration 
of eosinophils and Th2 T cells, preventing allergen-induced airway inflammation in a mouse 
model of asthma [112]. Tim-3 is constitutively expressed by mast cells and Tim-3 polyclonal 
antibody treatment enhanced production of Th2 cytokines such as IL-4, IL-6 and IL-13 from 
mast cells, without inducing degranulation [14].  
Several genetic studies on TIM-3 polymorphisms have suggested that TIM-3 is involved 
in the susceptibility to Th2 driven allergic diseases. In Korean populations, the -574T allele was 
found only in asthma and rhinitis patients (1 and 1.5% respectively), and the 4259T allele was 
found more frequently in rhinitis patients [36]. In a study on children from white or Hispanic 
parents, 22713A>G and 882C>T were shown to be associated with atopic dermatitis, but 
4259T>G was not [37]. Another study conducted on Chinese children-parent trios did not find 
evidence of an effect of individual TIM-3 polymorphisms on asthma susceptibility. However, 
haplotype analysis for the combination of three TIM-3 polymorphisms revealed that the G-G-G 
haplotype for rs10053538G4T, rs13170556A4G and rs9313441G4A was undertransmitted to 
asthmatic children [38].  Still, the role of TIM-3 in the pathogenesis of Th2 type allergic diseases 
is unclear. 
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1.6.4 Tolerance induction 
Tim-3 regulates tolerance in autoimmune models and allograft transplantation. Binding assays of 
full-length Tim-3-Ig and soluble Tim-3-Ig to immune cells revealed that Tim-3 ligands were 
expressed in terminally differentiated resting Th1 and Th2 CD4 T cells [34]. When CD4 T cells 
were activated in vitro, Tim-3L expression was downregulated in CD4
+
CD25
-
 T cells, but 
retained in CD4
+
CD25
+
 regulatory T cells. Blockade of Tim-3/Tim-3L interactions using Tim-3-
Ig fusion protein or anti-Tim-3 monoclonal antibody accelerated spontaneous development of 
diabetes in NOD mice. Induction of an allograft tolerance by blockade of co-stimulation (anti-
CD40L) and tolerance induction to a specific antigen by high dose antigen treatment were both 
impaired by blockade of Tim-3 or Tim-3 deficiency [33, 34]. It was found that galectin-9 is 
expressed on regulatory T cells, and blockade of Tim-3/galectin-9 suppressed the function of 
regulatory T cells [113, 114]. Not only Tim-3L but also Tim-3 itself is expressed on regulatory T 
cells, and the number of CD4
+
FoxP3
+
Tim-3
+
 T cell increases during allograft rejection. 
CD4
+
FoxP3
+
Tim-3
+
 T cells express more suppressive molecules like CTLA-4, IL-10 and TGF-β 
and are more potent in suppression of allo-specific effector T cells than CD4
+
FoxP3
+
Tim-3
-
 T 
cells. However, the suppressive capacity of Tim-3
+
 regulatory T cells was less than that of Tim-
3
-
 regulatory cells due to higher sensitivity to galectin-9-mediated cell death, and poorer survival 
of Tim-3
+
 regulatory T cells [51].  
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1.6.5 Chronic viral infection 
1.6.5.1 HIV 
A correlation between Tim-3 expression and dysfunctional phenotype of T cells in chronic viral 
infection was demonstrated first in HIV [115]. Tim-3 expression was upregulated in CD4 and 
CD8 T cells from PMBCs of early/acutely HIV-1 infected individuals and chronic progressors, 
compared to uninfected individuals and HIV-1 infected controllers. Specifically, Tim-3 
expression was upregulated in HIV-1 specific CD8 T cells compared to HIV-1 non-specific CD8 
T cells. The effect of anti-viral therapy on Tim-3 expression on CD8 T cell was examined. 
Among the seven subjects whose viral load was reduced after highly active antiretroviral therapy 
(HAART), the frequency of Tim-3
+
 cells was either declined or highly maintained in three and 
four subjects, respectively. However, in both groups, Tim-3 expression strongly correlated with 
CD38 expression (T cell activation marker) during the course of the therapy, implying that Tim-
3 expression relates to on-going T cell activation, rather than viral load.  
In the comparison of Tim-3 expressing and non-expressing T cells, Tim-3 expressing 
CD4 and CD8 T cells from HIV infected patients were dysfunctional in terms of proliferation 
and production of IFN-γ. Also it was found that STAT5, ERK and p38 activation were impaired 
in vitro, due to elevated basal phosphorylation of them. Similar to EAE/MS, Tim-3/Tim-3L 
blockade restored IFN-γ production and proliferation in HIV-1 specific T cells [115]. Tim-3 also 
appeared to regulate cytotoxic function of CD8 cells in HIV infection. Tim-3
+
 CD8 T cells 
contained more perforin in association with granules than Tim-3
-
 CD8 T cells, but there was a 
defect in degranulation, as shown by low surface expression of CD107a (lysosomal-associated 
membrane protein 1, LAMP1). Blockade of Tim-3 enhanced the expression of CD107a in CD8 T 
cells, and as a consequence, the cytotoxic activity against HIV-1 infected CD4 T cells was 
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restored [116]. In contrast to the negative effect of Tim-3 in HIV-immunity via suppression of 
HIV-specific T cells, inhibition of CD4 T cells by Tim-3 can be protective from HIV infection. 
Galectin-9 binding to Tim-3 downregulated surface expression of HIV co-receptors like CCR4, 
CXCR, α4β7 which are also activation markers of T cell, and upregulated p21, an inhibitor of 
cell cycle progression, inhibiting HIV entry to activated CD4 T cell and viral replication in 
already infected CD4 T cells [117].  
 
1.6.5.2 Herpes simplex virus (HSV) infection 
Recurrent herpes simplex virus infection is very common in humans and HSV establishes 
latency in peripheral neurons that lasts for the life of the host. Under certain conditions such as 
disease, stress, and UV, HSV reactivates and causes lesions in the peripheral tissue or 
asymptomatic shedding of virus [118]. In the HSV infected trigeminal ganglion (TG), CD8 T 
cells infiltrate to prevent HSV-1 from reactivation. The local HSV-specific CD8 T cells produce 
anti-viral IFN-γ, TNF-α, and granzyme B to suppress viral replication immediately upon 
reactivation [119, 120].  Since a major cause of HSV-related blindness is the lesions from 
recurring inflammation, Tim-3 might be the useful therapeutic target for prevention of blindness. 
After HSV-1 infection, Tim-3 is upregulated in CD4 T and CD8 T cells. Tim-3 blockade using 
monoclonal antibody (RMT3-23) and galectin-9 treatment, respectively, increases and reduces 
the severity of the stromal keratitis. Galectin-9 administration suppresses the keratitis by 
induction of apoptosis of both CD4 and CD8 T cells. Moreover, galectin-9 treatment promotes 
differentiation of FoxP3
+
 regulatory T cells, and the expansion of myeloid suppressor cells [121, 
122].  
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1.6.5.3 Lymphocytic Chorimeningitis virus (LCMV) infection 
The phenomenon of CD8 T cell exhaustion during chronic infection was first identified in 
LCMV infection model in mice [123]. Jin et al. demonstrated that Tim-3 participates in CD8 T 
cell exhaustion in synergy with PD-1. When C57BL/6 mice were acutely or chronically infected 
with LCMV Armstrong strain and clone-13, respectively, Tim-3 expression in GP33-specific 
(LCMV epitope) CD8 T cells was upregulated in both mice at the initial phase of infections. 
Over time, Tim-3 expression on the virus specific CD8 T cells decreases in acutely infected mice 
but Tim-3 expression was maintained over 60 days in chronically infected mice. Consistently, 
the frequency of Tim-3 and PD-1 double positive cells among GP33-specific CD8 T cells 
isolated from spleen, lung, and liver was upregulated and sustained during chronic infection. 
When the splenocytes from chronically infected mice were re-stimulated with LCMV peptide, a 
significant decrease in the frequency of IFN-γ, TNF-α, and IL-2 producing cells in Tim-3-PD-1+ 
CD8 T cells, and further decrease in Tim-3
+
PD-1
+
 CD8 T cells was found, in comparison to 
Tim-3
-
PD-1
-
 virus-specific CD8 T cells. Administration of anti-Tim-3 and anti-PD-1 into 
chronically LCMV infected mice for two weeks synergistically enhanced the proliferation and 
cytokine production in the virus-specific CD8 T cells. In addition, the dual blockade of Tim-1 
and PD-1 synergistically reduced the viral load, suggesting that blockade of Tim-3 along with 
PD-1,  is a promising measure to achieve better control for chronic viral infection [47]. 
1.6.6 Cancer 
Tumor causes persistent antigen stimulation, similar to chronic infection, resulting in dysfunction 
of tumor-specific CD8 T cells, thus Tim-3 negatively regulates antitumor activity of CD8 T cells. 
In mice, upregulation of Tim-3 and PD-1 expression was found in TILs from mice implanted 
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with CT26 solid colon adenocarcinoma. The frequency of IFN-γ, IL-2, and TNF-α producing 
CD8 TILs was lower among Tim-3
+
PD-1
+
 TILs than Tim-3
-
PD-1
-
 and Tim-3
-
PD-1
+
 TILs. 
Blockade of Tim-3 and PD-1 effectively restored the IFN-γ production upon ex vivo stimulation 
with anti-CD/CD28, and tumor growth in vivo [49]. Study of human samples, consistently, 
showed that Tim-3 expression was upregulated in NY-ESO-1, a tumor antigen,-specific CD8 T 
cells isolated from PBMCs of patient with advanced melanoma. Tim3
+
PD-1
+
NY-ESO-1
-
specific 
CD8 T cells were more dysfunctional than Tim-3
-
PD-1
+
 and Tim-3
-
PD-1
-
 NY-ESO-1
-
specific 
CD8 T cells in terms of IFN-γ, IFN-α, and IL-2 production upon ex vivo stimulation and Tim-
3
+
PD-1
+
NY-ESO-1 specific CD8 T cells were in high activation/differentiation status according 
to the activation marker expression such as CD38, HLA-DR, and CD57. Tim-3 blockade with 
anti-Tim-3 alone or with co-blockade of PD-1 restored the frequency of cytokine producing 
tumor-specific CD8 T cells upon stimulation with tumor antigen peptide (NY-ESO-1157-165) for 
six days.  In NSCLC, majority TILs expressing Tim-3 were regulatory T cells [50], and positive 
correlation between Tim-3 expression and poor prognosis was found[124].  
Recently, Tim-3 was shown to be expressed in tumor infiltrating dendritic cells and to 
bind to HMGB1, which inhibited the innate immune responses mediated by nucleic acid-sensing 
TLRs [104]. Kikushige et al. discovered that Tim-3 was expressed on most acute myeloid 
leukemic (AML) stem cells but not in normal hematopoietic stem cells and proposed Tim-3 as a 
promising surface molecule to specifically target acute myeloid leukemia. However, it was not 
determined whether Tim-3 has a role in the development of AML. 
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1.7 TIM-3 SIGNALING  
The cytosolic tail of Tim-3 has six tyrosine residues, Y256 of mouse Tim-3 (Y265 in human 
Tim-3) and the amino acid sequence surrounding Y256 is conserved. Van der Weyer et al. 
suggested tyrosine phosphorylation of the conserved tyrosine may be important in Tim-3 signal 
transduction. Y265 of the ectopically expressed human TIM-3 was phosphorylated by treatment 
with pervanadate, a potent inducer of phosphorylation, in HEK 293 cells. Phosphorylation of 
Y265 was upregulated by co-expression of Itk or galectin-9, suggesting that ligation of Tim-3 
with its ligand may induce tyrosine phosphorylation of Y265 and Itk may mediate the tyrosine 
phosphorylation [125].  Lee et al, showed human Tim-3 expression suppressed the activity of 
NFAT and transcription of AP-1 in Jurkat and human CD4 T cells when they were stimulated 
with  PMA/ionophore,  as a consequence, suppressed IL-2 production[126]. The inhibitory 
function of Tim-3 required the cytosolic tail of Tim-3, especially the conserved region with 
Y265 and Y262. Rangachari et al, reported that BAT3 as a molecule regulating Tim-3function. 
BAT3 associated with unphosphorylated Tim-3 and bound with active Lck. Ligation of Tim-3 
induced the dissociation of BAT with Tim-3 and Lck. BAT3 deficiency or knock-down 
suppressed the development of EAE in vivo. IFN-γ and IL-2 production was decreased in BAT 
deficient cells, while increased in BAT3 overexpressing cells. Therefore, BAT3 interacts with 
Tim-3 suppressing function of Tim-3, and released from Tim-3[127]. These data suggest that 
tyrosine phosphorylation is crucial for regulation of inhibitory Tim-3 function. However, the 
mechanism by which the tyrosine residues of Tim-3 cytosolic mediate signal and downstream 
target of Tim-3 are not known. 
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1.8 T CELL RECEPTOR SIGNALING 
1.8.1 T cell receptor complex 
T cell receptor (TCR) complex consist of a TCR heterodimer, two ζ chains, and two CD3 
heterodimers. TCR consists of highly variable α and β which recognize antigen epitope mounted 
on a MHC molecule. TCR α and β chains lack cytosolic tail, transmembrane domain of TCR α 
and β chains interact with ζ chains which have cytosolic tail containing three tyrosine 
phosphorylation motifs each. There are three CD3 chains, γ, δ, and ϵ, which form CD3γϵ and 
CD3δϵ heterodimers. ζ chains and CD3 chains contain conserved tyrosine phosphorylation 
motifs called an immunoreceptor tyrosine-based activation motif (ITAM, YxxL/Ix(6-
8)YxxL/I)[128], tyrosine phosphorylation of the motifs is induced by TCR-antigen engagement 
and mediate the recruitment of signaling molecules to TCR complex.   
1.8.2 Src family kinases (SFK) 
Lck and Fyn are members of SFKs, which phosphorylate ITAMs in TCR complexes. Both Lck 
and Fyn shares the common structures of SFK, which consist of SH2 domain, SH3 domain and a 
kinase domain [129]. Activity of SFKs is regulated by phosphorylation of dephosphorylation of 
tyrosine residues. Intracellular interaction between the C-terminal phosphotyrosine and SH2 
domain limit the access of substrate [130]. In T cells, dephosphorylation of the inhibitory 
tyrosine residue by CD45 phosphatase and phosphorylation by Csk activates and inhibits kinase 
activity of the SFKs, respectively [131, 132]. When Lck or Fyn are released from inhibitory 
conformation, autophosphorylation of the tyrosine residue in the loop between N- and C-
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catalytic lobes leads to conformational changes in kinase domain resulting in full activation of 
the kinases.  
Although Fyn has a partial role, Lck plays major role in initiation of TCR signaling by 
phosphorylating ITAMs in ζ chains and CD3. Lck constitutively interacts with CD4 or CD8 [133, 
134], and Fyn interacts with CD3 [135]. It has been suggested that Lck is brought to proximity of 
TCR by co-aggregation of CD4/CD8 with TCR. Also localization of membrane microdomains 
regulates phosphorylation of TCR by Lck and Fyn [136-138]. However, it is still unclear how 
phosphorylation of TCR complexes by Lck and Fyn is regulated upon TCR-antigen ligation. 
1.8.3 ZAP-70 and phosphorylation of adaptor proteins 
When Lck phosphorylates ITAMs in the intracellular domains of ζ chains, ZAP-70 is recruited to 
the phosphotyrosine via its SH2 domains [139] and activated by Lck [140]. The activated ZAP-
70 phosphorylates adaptor molecules LAT and SLP-76, which leads to assembly of LAT-GADS-
SLP-76 scaffolding complex [141, 142]. LAT-GAD-SLP-76 complex nucleate the formation of 
signalosomes which control activation of PLC-γ1 pathway, MAP kinase pathway, and 
cytoskeleton reorganization.   
1.8.4 PLC-γ1 and activation of transcription factors 
PLC-γ1 [143, 144] and Itk, a Tec kinase which phosphorylates and activates PLC-γ1 [145] are 
recruited to a LAT-GADS-SLP-76 complex. PLC-γ1 hydrolyze phosphatidylinositol 4,5-
bisphosphate(PIP2) to generate second messengers  inositol 1,4,5-trisphosphate (IP3) PIP2 and 
diacylglycerol (DAG). IP3 induces a Ca
2+
 release from ER.  Association of Ca
2+ 
bound 
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calmodulin activates phosphatase activity of calcineurin. The activated calcineurin 
dephoaphorylates NFAT transcription factors leading to nuclear translocation of NFAT [146].  
PKC-θ is also activate by and Ca2+. PKC-θ is recruited to DAG in plasma membrane, where 
PKC-θ phosphorylates Carma1. In turn, the phosphorylation facilitates formation of Carma1-
Bcl10-Malt1 complex resulting in activation of NF-κB pathway. DAG also recruits RasGRP to 
activate Erk pathway. Then the activation of Erk pathway induces expression and activation of c-
fos, which dimerizes with c-Jun leading to formation of AP-1 transcription factor.  
1.9  T CELL EXHAUSTION 
In the initial stage of infection, virus-specific naïve CD8 T cells, that encounter antigen 
differentiate into effector cells, which efficiently proliferate and produce effector molecules like 
IFN-γ, TNF-α, perforins and granzymes. After the infection is cleared acutely, the virus-specific 
CD8 T cell population shrinks and subsets of the T cells leave as memory cells, which can last a 
long-term period without a requirement for homeostatic cytokines IL-7 and IL-15, and can 
respond rapidly to the secondary antigenic challenge. On the contrary, if the infection is not able 
to be cleared but becomes chronic, the virus-specific CD8 T cells gradually lose their function: 
loss of ability to produce cytokine, less responsiveness to homeostatic cytokines, loss of 
proliferative potential, and apoptosis [147, 148]. During chronic infection, viral-specific T cells 
lose their polyfunctionality of cytokine production in a hierachial manner. For example, at the 
early stage of exhaustion, IL-2 and TNF-α production is diminished in the effector T cells while 
IFN-γ production was retained. Eventually, T cells lose production of IFN-γ at the late stage of 
exhaustion [149]. 
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Antigen specific stimulation of T cells seems to drive exhaustion. There were correlation 
between the viral load and the severity of loss of function [149]. mRNA microarray  analysis 
revealed that the mRNA profile of exhausted CD8 T cells is similar to the profile of effector 
CD8 T cells than that of naïve or memory T cells [150]. Higher level of NFATc1 mRNA was 
found exhausted CD8 T cells [150], and NFATc1 binds to promoter of PD-1 and regulates 
transcription of PD-1 [151].  
During chronic infection several inhibitory receptors such as PD-1 and CTLA-4 are 
expressed on the surface and mediate the dysfunction T cell dysfunction [152-157]. PD-1 is a 
transmembrane receptor which is expressed on activated T cells but also expressed on B cells, 
NKT cells [158]. PD-1 has two ligand, PD-L1 is broadly expressed both in lymphoid and non-
lymphoid cells, while PD-L2 is expressed in activated macrophage and DCs [159, 160]. PD-1 
contains immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-
based switch motif (ITSM) in its cytosolic tail. Ligation of PD-1 using anti-PD-1 inhibited 
activation of PI3K and Akt, which was dependent on a ITSM than a ITIM [161, 162]. SHP-1 and 
SHP-2 interaction with the cytosolic tail of PD-1 was found in primary murine B cells [163], 
Jurkat T cells [164], and in vitro yeast two hybrid system [165].  SHP-2 phosphorylation was 
upregulated by TCR/PD-1 ligation in primary human CD4 T cells [164]. However, it is still 
unclear whether PD-1 signaling is mediated by SHP-1 or SHP-2 in T cells, because SHP-1/2 
interaction with PD-1 in T cells was not demonstrated in physiological conditions. In addition, 
since SHP-1 and SHP-2 are involved in several other inhibitory signaling of T cell activation, 
there is a difficulty to prove whether inhibitory effect of PD-1 signaling is SHP-1/2-dependent 
using SHP-1/2 deficient model or by knock-down [166].  
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CTLA-4 is an inhibitory molecule shown to inhibit CD28 co-stimulation, whose 
deficiency in mouse resulted in spontaneous lymphoproliferation and fatal tissue destruction 
within 3-4 weeks of age [167, 168]. The cytosolic tail of CTLA-4 lacks ITIM or ITSM motif but 
has GVYVKM motif for AP-2 binding [169]. YVKM motif of CTLA-4 mediates the binding of 
PI3K, SHP-2 and PP2A [170]. Although CTLA-4 inhibits Akt activation, ligation of CTLA-4 did 
not inhibited PI3K. Inhibition of Akt by CTLA-4 was suppressed by treatment with okadaic acid, 
a PP2A inhibitor, suggesting CTLA-4 inhibits Akt via PP2A [161]. Cell-extrinsically, CTLA-4 
can competitively inhibit CD28 co-stimulation by binding to CD80 and CD86, ligands of CD28, 
with greater affinity. CLTA-4 binding to CD80 and CD86 can mediate the removal and 
degradation of CD80 and CD86 from APC by trans-endocytosis to T cells [171-173].  
1.10  STATEMENT OF THE PROBLEM 
Tim-3 has been implicated in the modulation of various immune conditions mediated by Th1 and 
Th17 CD4 T cells and CD8 T cells such as multiple sclerosis [44, 67, 107], type I diabetes [34], 
allograft rejection [33], chronic viral infection [47, 115, 116, 121], and tumor [48, 49, 104]. 
Moreover, Tim-3 is expressed by innate immune cells, and modulates production of Th2 
cytokines by mast cells [14], and LPS- and nucleic acid-recognizing TLR responses in APC [57, 
104, 174]. In general Tim-3 seems to function as an inhibitory receptor on T cells. However, 
depending on the type of cells and response it appears that Tim-3 has positive roles as well. Tim-
3 is an emerging therapeutic target for treatment of autoimmune disease, tumors, and infectious 
disease. However, the mechanisms by which Tim-3 signaling suppresses activation and effector 
cytokine production in T cells and how Tim-3 results in different outcomes in different type of 
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cells are not understood. Because of the promiscuity of the known Tim-3 ligands, various 
antibodies were developed and used to characterize the function of Tim-3 in place of the natural 
ligands of Tim-3. These antibodies have been described as “agonistic” or “antagonistic” by 
comparing their effects to the consequences of the treatment with Tim-3-Ig fusion protein, 
assuming that Tim-3-Ig blocks Tim-3/Tim-3L interaction. However, due to a lack of knowledge 
of Tim-3 function at cellular and molecular level, there is still confusion of the definition of 
“agonistic and antagonistic” antibody.  
To investigate the mechanism how Tim-3 signals are initiated and regulated, we 
generated and studied wild type Tim-3 constructs with serial deletion or point mutation at 
putative tyrosine phosphorylation sites. We intended to examine the influence of Tim-3 
expression on TCR signaling and to identify the residues which are required for the Tim-3 
function using the Tim-3 constructs. We also intended to identify the proteins interacting with 
the cytosolic tail of Tim-3, and to analyze the mode of the interaction. Then we aimed to identify 
the signaling molecules downstream of the TCR modulated by Tim-3 expression. The results that 
we collect from these experiments will help us to understand how Tim-3 modulates T cell 
signaling and exert inhibition of T cell function. Also this study may help to identify therapeutic 
targets for T cell mediated immune conditions like autoimmune diseases, cancer and, chronic 
infection. 
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2.0  TIM-3 TYROSINE PHOSPHORYLATION AND STRUCTURE FUNCTION 
2.1 INTRODUCTION 
Numerous studies revealed that Tim-3 functions as a negative regulator of Th1 and Th17 CD4 T 
cells and CD8 T cell mediated immune responses. Tim-3 expression is upregulated on activated 
T cells, and blockade of the Tim-3/Tim-3L using recombinant Tim-3 fusion protein or 
antagonistic Tim-3 antibody increases the production of cytokines such as IFN-γ, IL-2, IL-17, 
and TNF-α and  [45, 47, 48, 72, 75, 175], suggesting that Tim-3 is an inhibitory receptor. During 
prolonged T cell activation, such as chronic infection, inhibitory receptors like PD-1 and 2B4 are 
expressed on the surface of T cells leading to suppression of T cell function [147]. Some of these 
inhibitory receptors contain ITIM or ITSM, which recruit phosphatases upon tyrosine 
phosphorylation [162, 176, 177]. However, Tim-3 does not have conventional activating or 
inhibitory motifs, like ITAM, ITIM or ITSM in its cytosolic tail. It has not been determined yet 
whether Tim-3 generates inhibitory signaling like PD-1, or 2B4. In addition, it was not known 
how Tim-3 signal transduction is initiated and how Tim-3 signaling leads to inhibition of T cell 
function. Our group previously showed that tyrosine phosphorylation (pY276) of Tim-1 
cytosolic tail is required for the co-stimulatory function of Tim-1 and recruitment of downstream 
molecules [13, 17]. When examining the sequence of Tim-3, we found that the amino acid 
residue sequences surrounding the tyrosine residue in Tim-1 are conserved in Tim-3. Therefore, 
we hypothesized that the tyrosine residues are important for Tim-3 function. van de Weyer et al. 
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demonstrated that galectin-9 treatment induces phosphorylation of TIM-3 at Y265 in 293T cells 
[125]. However, the function of Tim-3 in T cell activation, the role of tyrosine phosphorylation 
in the regulation of Tim-3 function, and the identity of the kinase responsible for the tyrosine 
phosphorylation were not determined.  
In this section I will describe the function of Tim-3 in modulation of downstream TCR 
signaling in T cell lines, the domains and tyrosine residues required for Tim-3 function, and 
regulation of phosphorylation of the tyrosine residues in Tim-3 cytosolic tail.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Cell lines and cell culture 
Jurkat T cells and Jurkat variants were cultured in RPMI-1640 (Mediatech) supplemented with 
5% bovine growth serum (BGS, Hyclone)  100U/ml penicillin  and 100μg/ml streptomycin. D10 
Th2 T cell clone was cultured in RPMI-1640 (Mediatech) supplemented with 10% BGS, 
100U/ml penicillin, 100μg/ml streptomycin, nonessential amino acid, 1mM sodium pyruvate, 
55μM 2-mercaptoechanol (Life sciences), and 10mM HEPES (Fisher). Tet-on Tim-3 Jurkat T 
cells were maintained in 0.8μg/ml puromycin, and Tim-3 expression was induced with 1.5μg/ml 
doxycycline for 2 days. 
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2.2.2 Antibodies and reagents 
C305 antibody to Jurkat TCR was obtained from Dr. Arthur Weiss (UCSF, CA), human anti-
CD28 were from Life Sciences. Biotinylated anti-mouse CD3 (2C11) and CD28 (37.51) were 
from eBioscience, and anti-mouse CD4 (L3T4) was from eBioscience. Streptavidin was from 
Zymed Laboratories. Anti-Flag M2 antibody, anti-Flag M2 agarose, and β-actin antibody were 
from Sigma Aldrich, polyclonal goat anti-mouse Tim-3 antibody was from R&D systems.  anti-
phospho-tyrosine (4G10) was from Millipore. HRP conjugated goat anti-mouse antibody and 
donkey anti-goat antibody were from Thermo scientific and Jackson Immunoresearch 
respectively. PMA, ionomycin and doxycycline were from Calbiochem and D-luciferin was from 
Thermo scientific. Peptide N-glycosidase F (PNGaseF) was from New England Biolabs. 
2.2.3 DNA constructs 
Murine Tim-3 sequence corresponding to each full-length and deletion Tim-3 without signal 
sequence were amplified by PCR and cloned in to pCDEF3 vector with CD8 signal sequence and 
Flag-tag sequence in N-terminus side. Point mutant constructs were generated using 
Quickchange site-directed mutagenesis kit (Stratagene). CD2-Tim-3 chimera was generated by 
fusing the ectodomain and transmembrane domains of human CD2 with the cytoplasmic tail of 
murine Tim-3. Sequences of all constructs were verified by automated sequencing. Tetracycline-
inducible Tim-3 construct was generated by PCR amplification of Flag-tagged Tim-3 and 
cloning into pBI-EGFP vector (Clontech) 
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2.2.4 Generation of Tet-on inducible Tim-3 Jurkat cell line 
Parental Jurkat T cells were transfected with Tet-on transactivor (rtTA) vector and empty 
pCDNA 3.1 vector with Neo selection marker, and stable cells were isolated by G418 selection. 
The rtTA stable Jurkat T cells were transfected with pBI-EGFP-Tim-3 vector along with pIRES-
puro (Clontech) and clones were selected with limiting dilution and 1μg/ml puromycin selection. 
Inducible expression of Tim-3 in the selected clones was screened by flow cytometry. 
2.2.5 Luciferase reporter assay 
2x10
6
 Jurkat or D10 cells were transfected with 15ug of NFAT/AP-1, NF-κB, NFAT, or AP-1-
luciferase reporter, and Tim-3 constructs by electroporation at 260V/950μF(Jurkat) or 
250V/950μF(D10). The day after transfection, 5x105 cells were stimulated with anti-human TCR 
(C305)/CD28 antibodies (Jurkat) or biotinylated anti-mouse CD3/CD4/CD28 and streptavidin 
(D10) for six hours in round bottom 96 well plates. After freezing and thawing cycle, luciferase 
assay was performed in 5mM ATP, 10mM MgCl2, and 1mM D-luciferin using luminometer 
(Berthold) 
2.2.6 Co-immunoprecipitation and western blotting 
293T cells transfected with Flag-Tim-3 constructs and Jurkat T cells inducibly expressing Flag-
Tim-3 (Tet-on Tim-3 Jurkat) were stimulated with pervanadate or monoclonal antibody specific 
for Jurkat TCR (C305.2), then lysed with ice-cold 1% NP-40 lysis buffer (20mM Tris-HCl, pH 
7.5, 150mM NaCl) supplemented with AEBSF, aprotinin, leupeptin, pepstatin, sodium fluoride, 
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sodium orthovanadate, and β-glycerophosphate. Lysates were then incubated on ice for 10 min 
before being cleared by centrifugation. The lysates were incubated with anti-Flag agarose for 
overnight. After beads were washed with lysis buffer the incubated with 2X Sample buffer (Bio-
Rad, Hercules, CA) at 37’C for 10min. the supernatants were loaded onto 10% SDS-PAGE gels. 
Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, probed with anti-
Tim-3, or anti p-Tyr 4G10 antibody, and detected with anti-mouse HRP or anti-goat HRP. Blots 
were imaged on a Kodak ImageStation 4000R system.  
 
2.3 RESULTS 
2.3.1 Tyrosine 256 and 263 are responsible for Tim-3 function to enhance NFAT/AP-1 and 
NF-κB reporter activity 
The amino acid sequence of cytosolic tail of Tim-3 is highly conserved and both mouse and 
human Tim-3 contain six tyrosine residues in their cytosolic tails at residues 219, 256, 263, 271, 
272, and 274 (positions in mouse Tim-3, Figure 4A). Previously, we demonstrated that Y276 of 
Tim-1 is critical for co-stimulatory function of Tim-1 and its phosphorylation was induced by 
SFK Lck [13]. Comparing the sequence of Tim-3 and Tim-1, we could find that the conserved 
tyrosine residue at the position of Y256 analogous to Y276 of Tim-1 is surrounded by acidic 
amino acid residues. When we searched for possible phosphorylation sites in the cytosolic tail of 
Tim-3 with a motif prediction algorithms, both Y256 and Y263 were predicted to be 
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phosphorylated (Figure 4B). Therefore, we hypothesized that the conserved region surrounding 
the two tyrosine residues may be required to couple Tim-3 to downstream signaling.   
To determine the requirement of the conserved sequence for Tim-3 signaling, we 
generated Flag-tagged serial deletion mutants of Tim-3. Truncation 1 construct (T1) contains two 
tyrosine residues in the conserved region (Y256 and Y263), but lacks three terminal tyrosine 
residues (Y271, Y272, and Y274). Truncation 2 construct lacks all five tyrosine residues from 
the C-terminus leaving only a membrane proximal tyrosine (Figure 5). Jurkat T cells which do 
not endogenously express Tim-3 were transfected with Flag-tagged full-length Tim-3, or the 
serial deletion mutants of Tim-3, along with NFAT/AP-1 luciferase reporter, and stimulated the 
T cells with anti- human TCR and CD28 antibodies. Although Tim-3 was known as an inhibitory 
molecule in Th1 immune responses, surprisingly, we found that ectopic expression of WT Tim-3 
in Jurkat T cells resulted in enhancement of NFAT/AP-1 reporter activity induced by TCR/CD28 
stimulation rather than inhibition. T1 Tim-3 mutant not only retained the ability to augment 
NFAT/AP-1 activation by TCR/CD28 stimulation, but slightly, and reproducibly enhanced 
NFAT/AP-1 activation more than WT full-length Tim-3. Meanwhile, the T2 deletion completely 
abolished the ability of Tim-3 to augment NFAT/AP-1 reporter activity, suggesting that the 
conserved region near Y256 and Y263 is crucial for function of Tim-3 in the modulation of 
downstream TCR signaling, and that the C-terminus, containing three terminal tyrosine residues, 
may be involved in negative regulation of Tim-3 function (Figure 6A).   
Since we observed a functional requirement for the Tim-3 conserved region around Y256 
and Y263, which are predicted as tyrosine phosphorylation sites, we hypothesize that tyrosine 
phosphorylation of the two tyrosine residue mediates Tim-3 signal. To determine the role of the 
tyrosine residues in Tim-3, I point mutated the tyrosine residues at position of 256 and 263 to 
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phenylalanine, either individually or together (Figure 5). The full-length and T1 Tim-3 constructs 
carrying either a Y256F or Y263F point mutation enhanced NFAT/AP-1 activation by 
TCR/CD28 stimulation, at levels equivalent to WT full-length, or T1 Tim-3. However, the 
Y256/263F double point mutant of Tim-3 significantly, but not completely, lost this function. 
Although the T1 truncation enhanced Tim-3 activity, paradoxically, when the Y256/263F double 
mutation was combined with T1 truncation I observed a loss of Tim-3 function, which was more 
severe effect than seen with the full-length Y256/Y263F double mutation (Figure 6B). We also 
examined the modulation of NF-κB luciferase reporter activity by Tim-3 expression in Jurkat T 
cells, and found it to be very similar to the results obtained with an NFAT/AP-1 reporter (Figure 
7C).  
Consistently, we observed the same effects of expression of each Tim-3 construct in a 
both NFAT/AP-1 and NF-κB reporters in non-transformed D10 Th2 T cell clones (Figure 7B and 
D).  In addition, although we observed similar modulation of basal NFAT/AP-1 and NF-κB 
reporter activity by WT and Tim-3 mutants in Jurkat T cells, in the absence of TCR/CD28 
stimulation, the extent of modulation by Tim-3 constructs was profoundly different in the 
presence of TCR stimulation. (i.e. co-stimulation). These results suggest that the two tyrosine 
residues Y256 and Y263 are responsible for Tim-3 function to enhance NFAT/AP-1 and NF-κB 
activation, by amplifying TCR signaling, and that Tim-3 signaling converges with TCR signaling 
via common  signaling pathways upstream of NFAT/AP-1 and NF-κB.  
I tested whether the conserved region near Y256 and Y263 and C-terminus region of 
Tim-3 cytosolic tail are sufficient for Tim-3 function. I generated another Tim-3 mutant lacks the 
region between transmembrane domain and conserved region (Δ216-244, Figure 5) and tested its 
effect to NFAT/AP-1 reporter activity in D10 T cells.  Δ216-244 deletion of Tim-3 led to 
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complete loss of the positive Tim-3 function equivalent to T2 deletion and Δcyto deletion, which 
lacks most of the cytosolic tail of Tim-3 (Figure 8). 
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Figure 4. Sequence of Tim-1 and Tim-3 cytosolic tails and prediction of phosphorylation motifs 
(A) Sequence of Tim-1 and Tim-3 cytosolic tails. (B) phosphorylation sites were predicted with NetPhos 
(http://www.cbs.dtu.dk/services/NetPhos/) (C) kinase-specific prediction of phosphorylation sites was done with 
NetPhosK (http://www.cbs.dtu.dk/services/NetPhosK/) 
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Figure 5. Schematic diagram of Flag-tagged Tim-3 and mutant Tim-3 constructs 
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Figure 6. Modulation of NFAT/AP-1 reporter activity by WT and mutant Tim-3 expression in Jurkat T cells 
(A) Jurkat T cells were transfected with an NFAT/AP-1 luciferase reporter, plus the indicated Tim-3 constructs. The 
next day, cells were left unstimulated or stimulated with anti-TCR/CD28 mAb’s. Luciferase activity is presented as 
relative light unit (A) and the percentage of the maximal response, obtained with PMA/ionomycin stimulation (B). 
(A, right panel) Surface expression of the indicated Tim-3 constructs was analyzed by anti-Flag staining and flow 
cytometry.   Average results (± SD) from triplicates are shown (P-value vs. WT: NS, P>0.05; *, P<0.05; **, P<0.01; 
***, P<0.01) (♦♦♦, P<0.001) 
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Figure 7. Requirement of Y256 and Y263 of Tim-3 to potentiate TCR signaling 
(A, C) Jurkat T cells were transfected with an NFAT/AP-1 (A) or NF-κB (C) luciferase reporter, plus the indicated 
Tim-3 constructs. (B, D) D10 T cells were also transfected with an NFAT/AP-1 (B) or NF-κB (D) reporter and the 
indicated Tim-3 constructs.  The next day, cells were left unstimulated (white bars) or stimulated with anti-
TCR/CD28 mAb’s (black bars). Luciferase activity is presented as the percentage of the maximal response, obtained 
with PMA plus ionomycin. Average results (± SD) from triplicates are shown (*, P<0.05; **, P<0.01; ***, P<0.01)  
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Figure 8. Requirement of region between transmembrane domain and the conserved domain 
D10 T cells were also transfected with an NFAT/AP-1 reporter and the indicated Tim-3 constructs.  The next day, 
cells were left unstimulated (white bars) or stimulated with anti-TCR/CD28 mAb’s (black bars). Luciferase activity 
is presented as the percentage of the maximal response, obtained with PMA plus ionomycin. Average results (± SD) 
from triplicates are shown. 
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2.3.2 Tim-3 induces AP-1 reporter activity independently of TCR signaling. 
Both NFAT and AP-1 are downstream of TCR signaling, NFAT is regulated by the Calcium 
signaling pathway and AP-1 is regulated by MAP kinase pathway. To further dissect the 
signaling pathways downstream Tim-3, I examined the role of Tim-3 in activation, of NFAT and 
AP-1 separately. I performed luciferase reporter assays for NFAT and AP-1 as described above. 
The results from NFAT reporter assays were similar to NFAT/AP-1 and NF-κB reporter assays. 
That is, ectopic expression of WT and T1 Tim-3 were capable to augment NFAT reporter 
activity in Jurkat T cells, while T2 was not (Figure 9A and B).  
Interestingly, WT Tim-3 expression in Jurkat T cells led to upregulation of AP-1 reporter 
activity independently of TCR/CD28 stimulation (Figure 9C and D). T1 Tim-3 was at least as 
efficient as WT Tim-3 in enhancing NFAT activity, but T1 Tim-3 was less potent in 
enhancement of AP-1 reporter activation compared to WT Tim-3. These data suggest that the 
region near Y256/263 of cytosolic tail of Tim-3 mediate the enhancement of calcium-NFAT 
pathway in a TCR stimulation-dependent manner and that the C-terminal region of the cytosolic 
tail of Tim-3 containing Y271/272/264 partially mediate the enhancement of MAP kinase-AP-1 
pathway in a TCR dependent manner.  
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Figure 9. Differential activation of NFAT and AP-1 reporter activity by Tim-3 
(A, B) Jurkat T cells were transfected with an NFAT and plus the indicated Tim-3 constructs. (C, D) Jurkat T cells 
were transfected with an AP-1 and plus the indicated Tim-3 constructs. The cells were stimulated anti-TCR/CD28 
antibodies, PMA or ionomycin. Luciferase activity is presented as the percentage of the maximal response, obtained 
with PMA/ionomycin (A, B) or relative light unit (C, D). Average results (± SD) from triplicates are shown (*, 
P<0.05; **, P<0.01; ***, P<0.01)  
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2.3.3 Cytosolic tail of Tim-3 is sufficient to induce Tim-3 signaling 
We demonstrated above that the cytosolic tail of Tim-3 mediated signal transduction to modulate 
TCR signaling. I next assessed if expression of the cytosolic tail is sufficient for Tim-3 signaling. 
I generated Flag-tagged Tim-3 constructs lacking IgV domain (ΔIgV), and most of the 
ectodomain (Δecto). Despite the deletion, both ΔIgV and Δecto Tim-3 constructs retained the 
ability to enhance TCR signaling, to activate NFAT/AP1 (Figure 10A). When I crosslinked the 
surface-expressed Tim-3 using anti-Flag-antibody, this did not alter the function of WT, but a 
slight enhancement in function was observed with the Tim-3 ΔIgV construct. However, this 
crosslinking effect was not seen with the Tim-3 Δecto construct.  Expression of a chimeric 
protein consisting of the echo-and transmembrane domains of an unrelated protein CD2 and the 
Tim-3 cytosolic tail did upregulate NFAT/AP-1 reporter activity in a dose-dependent manner, 
suggesting that ectopic expression of the Tim-3 cytosolic tail in Jurkat T cells is sufficient to 
initiate Tim-3 signaling (Figure 10B). 
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Figure 10. Role of Tim-3 cytosolic tail in Tim-3 signaling function. 
 (A) Effect of IgV and ectodomain deletions on Tim-3 co-stimulation of NFAT/AP-1. (B) Co-stimulation of 
NFAT/AP-1 activation by a CD2-Tim3 chimera. Jurkat T cells were transfected with an NFAT/AP-1 reporter and 
the indicated constructs and then stimulated as indicated before determination of luciferase activity. ). Average 
results (± SD) from triplicates are shown (*, P<0.05; **, P<0.01; ***, P<0.01) 
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2.3.4 Tyrosine 256 and 263 are available for tyrosine phosphorylation 
To address how tyrosine phosphorylation might mediate Tim-3 signaling, I next examined the 
tyrosine phosphorylation of the Tim-3 cytosolic tail. I stimulated 293T cells transiently 
expressing Flag-tagged WT, T1 and T2 Tim-3 proteins and immunoprecipitated (IP’d) with anti-
Flag agarose. After SDS-PAGE and western blotting, the IP’d Tim-3 proteins were probed with 
anti-phosphotyrosine antibody and anti-Tim-3 antibody. Tim-3 proteins appear as large smear 
over 50kDa (glycosylated) and a condensed band under 40kDa (unglycosylated). 
Phosphorylation of WT Tim-3 was induced by pervanadate treatment and the phosphorylation 
was partially diminished in T1 Tim-3 and completely abolished in T2 Tim-3 (Figure 11A).  
To focus on the phosphorylation of Y256 and Y263, I assessed the phosphorylation of 
point mutants of Tim-3 in the T1 deletion background in 293T cell. Again, I observed 
pervanadate-induced tyrosine phosphorylation of T1 Tim-3. The Y256F mutation, but not Y263F 
mutation, resulted in drastic loss of tyrosine phosphorylation of T1 Tim-3, indicating that Y256 
may be the major phosphorylation site for Tim-3. However, considering the residual 
phosphorylation in T1:Y256 mutant and complete loss of the phosphorylation in T1:Y256/263F 
(2YF), I conclude that Y263 is still available for phosphorylation (Figure 11B).  
Finally, I investigated tyrosine phosphorylation in Jurkat T cells, which does not express 
endogenous Tim-3. For these experiments, I generated Jurkat T cells in which expression of 
Tim-3 is inducibly driven by a Tet-on transactivator (Tet-on Tim-3 Jurkat cell). The Tet-on Tim-
3 Jurkat T cells were treated with doxycycline to induce the Tim-3 expression and stimulated 
with anti-TCR and CD28 crosslinking antibody. IP’d Tim-3 was incubated with PNGaseF to 
remove glycosylation, then probed with antibody to phosphotyrosine and Tim-3. I observed that 
tyrosine residue(s) in Tim-3 were basally phosphorylated in the unstimulated Tet-on Tim-3 
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Jurkat T cells, and the tyrosine phosphorylation was modestly upregulated by crosslinking of 
TCR and CD28. Here I demonstrated that tyrosine residues, especially Y256 and Y263 were 
available for phosphorylation, and tyrosine residues of Tim-3 were basally, and also inducibly, 
phosphorylated in Jurkat T cells (Figure 11C).  
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Figure 11. Tyrosine phosphorylation of Tim-3 cytosolic tail 
(A and B) 293T cells were transfected with the indicated Flag-tagged Tim-3 constructs and then split and left 
unstimulated or treated with pervanadate. Lysates were prepared and subjected to IP with an anti-Flag antibody, 
followed by SDS-PAGE and Western blotting. Blots were first probed for Tim-3 (lower panel) and then stripped and 
reprobed with an anti-phosphotyrosine antibody (upper panel). (C) Parental Jurkat T cells or Tet-on Tim-3 Jurkat T 
cells were stimulated as indicated and prepared for IP and Western blotting as described above. After IP, samples 
were treated with PNGaseF F prior to SDS-PAGE 
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2.4 DISCUSSION 
Studies of Tim-3 signaling have been very limited and the downstream targets of Tim-3 
remained unknown. Cross-linking of Tim-3 with a monoclonal agonistic antibody (5D12) 
induced phosphorylation of ERK in a Th1 T cell clone AE7 and in a D2SC1 dendritic cell line 
[57]. However, since Tim-3 is known as a negative regulator of Th1 and CD8 T cell responses, it 
was expected that Tim-3 signaling would play a suppressive role in T cell signaling. Surprisingly, 
we found that ectopic expression of Tim-3 upregulated activation of major transcription factors 
involves in T cell function, like NFAT, AP-1, and NF-κB not only in Jurkat T cells but also in 
D10 a non-transformed T cell clone. Tim-3 expression could enhance basal NFAT, NFAT/AP-1 
and NF-κB reporter activities at low levels in the absence of TCR/CD28 stimulation, but the 
extent of the enhancement of the reporter activities was dramatically increased in the presence of 
TCR/CD28 stimulation. T1 constructs were more potent in enhancement of NFAT/AP-1, NFAT 
and NF-κB reporter activity, suggesting that the C-terminus region, containing three tyrosine 
residues, has an element which is involved in inhibition of Tim-3 function. However, as 
somewhat paradoxically, the T1:Y256/Y263 mutation led to severe ablation of Tim-3 function. 
Unlike other reporters we tested, activation of a pure AP-1 reporter by Tim-3 did not require the 
TCR/CD28 stimulation. In addition T1 deletion resulted in decreased Tim-3 function to 
upregulate AP-1 reporter activity. Thus, we hypothesize that the conserved region around Y256 
and Y263 recruits one or more signaling molecules intersecting downstream of the TCR pathway, 
and the C-terminal region of Tim-3 mediates signal transduction to a MAP kinase pathway 
bypassing TCR signaling (Figure 12). 
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For the positive function of Tim-3, two tyrosine residues two tyrosine residues, Y256 and 
Y263, surrounded by a conserved sequence, were required and the two tyrosine residues were 
available for phosphorylation. These results suggest that phosphorylation of Y256 and Y263 
couples Tim-3 to TCR signaling pathways and Tim-3 signaling intersects to the common 
upstream of NFAT and NF-κB pathway (Figure 12).   
Note that Tim-3 expression alone was sufficient to initiate Tim-3 signaling. One 
possibility is that a Tim-3 ligand is expressed on Jurkat T cells. Galectin-9 expression is 
detectable in resting Jurkat T cells and upregulated by PMA stimulation [178] and exposure to 
PS on the surface of dead cells after transient transfection is expected. However, I observed that 
expression of Tim-3 constructs lacking the IgV domain or ectodomain could also initiate the 
activating signaling. Due to excess number of molecules on the surface, formation of Tim-3 
complexes may occur in the transient overexpression conditions bypassing the requirement of 
ligand. Another possibility is that Tim-3 has dual function. Tim-3 may induce activating signals 
in the presence of ligand but inhibitory signals in the absence of ligand. We observed when Tim-
3 was retro-virally expressed in primary murine CD4 T cells, augmentation of IFN-γ production 
by Tim-3 was inhibited by agonistic Tim-3 antibody (5D12) [179]. I attempted to crosslink of 
Flag-tagged Tim-3 in Jurkat T cells, but the crosslinking of Tim-3 constructs with anti-Flag mAb 
failed to enhance or repress the positive function of full-length and Δecto Tim-3 constructs, 
rather, crosslinking slightly enhanced the function of ΔIgV domain Tim-3 constructs, while IgV 
domain interacts with the known ligands. These results might imply that the IgV domain might 
inhibit multimerization of Tim-3 or association of Tim-3 with other surface molecules or that 
Tim-3 ligand binding to IgV domain is involved in the inhibitory signal.  
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Next I determined that the two tyrosine residues (Y256 and Y263) responsible for 
positive Tim-3 function were available for tyrosine phosphorylation and that tyrosine 
phosphorylation of Tim-3 is inducible by TCR/CD28 stimulation in Jurkat T cells. These 
observations support the model that tyrosine phosphorylation of its cytosolic tail couples Tim-3 
to enhancement of T cell activation. Interestingly, Tim-3 was basally phosphorylated in resting 
Jurkat T cells and the extent of the TCR-inducible phosphorylation was relatively moderate, 
while the impact of Tim-3 expression on the activation of TCR signaling was more profound. 
Thus, there might be other mechanisms in addition to tyrosine phosphorylation that regulate the 
Tim-3 function, like its localization or the regulation of molecules recruited to Tim-3. 
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Figure 12. Model of activation of transcription factors downstream TCR signaling 
Augmentation of NF-κB and NFAT activity by Tim-3 signaling requires activation of proximal TCR signaling, 
while augmentation of AP-1 activity by Tim-3 is TCR-independent. (A) In the absence of TCR signaling, Tim-3 
signaling upregulates AP-1 reporter activity is upregulated by Tim-3, but cannot upregulated NF-κB, NFAT/AP-1 
and NFAT reporter activity. (B) In the presence of TCR signaling,, Tim-3 signaling enhances NF-κB, NFAT, and 
NFAT/AP-1 activity in a TCR signaling dependent manner and AP-1 reporter activity in both TCR-dependent and –
independent manner. 
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3.0  IDENTIFICATION OF TIM-3 INTERACTING MOLECULES 
3.1 INTRODUCTION 
Phosphorylation of amino acid residues with side chains containing hydroxyl groups is one of the 
most common post-translational modifications regulating cell signaling. Phosphorylation can 
turn “on” or “off” the activity of proteins by changing the conformation of a proteins or creating 
a binding site for a protein-protein interaction. In antigen receptor signal transduction in immune 
cells, including T cells, tyrosine phosphorylation plays a key part. The signature motifs for 
tyrosine phosphorylation called immunoreceptor tyrosine-based activation motif (ITAM, 
YxxL/Ix(6-8)YxxL/I) and immunoreceptor tyrosine-based inhibitory motif (ITIM, 
S/I/V/LxYxxI/V/L) are found in many activating or inhibitory receptors. For example, CD3-ζ of 
TCR contains three ITAM motifs [128]. Engagement of MHC molecules loaded with specific 
antigen induces the tyrosine phosphorylation of the ITAM motifs by SFK Lck or Fyn [134, 180]. 
Then the Syk family kinase ZAP-70 is recruited to the phosphotyrosine residues, leading to 
activation of TCR signaling, in which, the SH2 domains in ZAP-70 mediate the binding to 
phosphotyrosine [181]. The SH2 domain is a specialized domain that interacts with 
phosphorylated tyrosine, which is found in many kinases and adaptor proteins [182]. SH2 
domain mediates inter-protein interactions to regulate the localization of proteins, and also 
mediate intra-protein interactions to regulate conformation of proteins. Although, Tim-3 does not 
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have a typical ITAM or ITIM motif, it has several putative tyrosine phosphorylation sites. Y276 
of Tim-1, which is similar in context to Y256 of Tim-3, is available for tyrosine phosphorylation, 
and its phosphorylation mediates the recruitment of PI3 kinase [17]. Therefore, we hypothesized 
that phosphorylation of tyrosine residues in the cytosolic tail of Tim-3 recruits signaling 
molecules with SH2 domains.  
In this study, we identify signaling molecules interacting with phosphorylated tyrosines 
of Tim-3 via SH2 domains, and a kinase responsible for tyrosine phosphorylation of Tim-3. 
3.2 MATERIALS AND METHODS 
3.2.1 Cell lines and cell culture 
293T cells were cultured in DMEM (Mediatech) supplemented with 10% bovine growth serum 
(BGS, Hyclone) and 100U/ml penicillin, 100μg/ml streptomycin.  Parental Jurkat T cells and 
Jurkat variants were cultured in RPMI-1640 (Mediatech) supplemented with 5% bovine growth 
serum (BGS, Hyclone) and 100U/ml penicillin, 100μg/ml streptomycin.  
3.2.2 Antibodies and reagents 
C305 antibody to Jurkat TCR was obtained from Dr. Arthur Weiss (UCSF, CA), human anti-
CD28 were from Life Sciences. Anti-Flag M2 antibody, anti-Flag M2 agarose, and β-actin 
antibody were from Sigma Aldrich. Polyclonal anti-mouse Tim-3 was from R&D systems. Anti-
Fyn and p85 antibodies were from Millipore. HRP conjugated goat anti-mouse antibody was 
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from Thermo scientific, and donkey anti-goat, donkey anti-rabbit antibody were from Jackson 
Immunoreserach respectively. HRP conjugated Protein A was from GE. PMA and ionomycin 
were from Calbiochem and D-luciferin was from Thermo scientific. 
3.2.3 SH2 domain array 
Membranes with 38 recombinant human SH2 domains were purchased Panomics (Santa Clara, 
CA) and blotted following the manufacturer’s instruction. Biotinylated synthetic Tim-3 peptide 
was generated at the University of Pittsburgh peptide Synthesis core facility (biotin-
SEENIpYTIEENVpYEVENSN) and openbiosystems (biotin-EVENSNEpYpYCpYVNSQQPS).  
Tim-3 peptides were incubated with the membrane at 0.33μg/ml with or without 200mM phenyl 
phosphate. 
3.2.4 Co-immunoprecipitation and western blotting 
293T cells transfected with Flag-Tim-3 constructs, Jurkat T cells stably expressing Tim-3, and 
JHM1 cells, a Jurkat variant expressing muscarinic receptor 1, transiently transfected with Tim-3 
constructs were stimulate with pervanadate or monoclonal antibody specific for Jurkat TCR 
(C305.2), then lysed with ice-cold 1% NP-40 lysis buffer (20mM Tris-HCl, pH 7.5, 150mM 
NaCl) supplemented with AEBSF, aprotinin, leupeptin, pepstatin, sodium fluoride, sodium 
orthovanadate, and β-glycerophosphate. Lysates were then incubated on ice for 10 min before 
being cleared by centrifugation and supernatant were incubated with anti-Flag M2 agarose for 
4hr or overnight. After Agarose beads were washed with lysis buffer supplemented with protease 
inhibitor and phosphatase inhibitor, 2X Sample buffer (Bio-Rad, Hercules, CA) was added to the 
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beads and incubated at 37’C for 10min to elute the capture protein. The supernatant was 
subjected onto 10% SDS-PAGE gels. Proteins were transferred onto polyvinylidene difluoride 
(PVDF) membranes. The membranes were probe with Fyn or p85 antibodies and detected with 
HRP conjugated protein A 
3.2.5 NMR spectroscopy 
Fyn-SH2 domain was expressed as N-Term-GST fusion protein in BL21 cells in 
15
N minimal 
media, with 18hrs induction at 17’C with Isopropyl β-D-1-thiogalactopyranoside(IPTG). The 
protein is purified on GSH column, following which the GST-tag is cleaved by thrombin 
cleavage at RT. The Fyn-SH2 protein is further enriched by size exclusion chromatography to 
>95% purity (50mM Tris pH8.0, 150mM NaCl, 2mM DTT, 0.02% NaN3). Purified Fyn was 
concentrated and dialyzed against the NMR buffer (50mM Na2HPO4 pH 6.5, 5mM DTT). 
Unphosphorylated and phosphorylated Tim-3 peptides (SEENIYTIEENVYEVENSN and 
SEENIpYTIEENVpYEVENSN) were generated by OpenBiosystems (Huntsville, AL). 
15
N 
HSQC of the purified Fyn SH2 domain (200uM) alone or with either unphosphorylated Tim-3 
peptide(1.2mM) or phosphorylated Tim-3 peptide (1.12mM) were analyzed as previously 
described [183]. 
3.2.6 Kinase assay 
Flag-tagged full-length Tim-3 was expressed from 293T cells, IP’d with anti-Flag M2 agarose, 
and eluted with Flag peptide. Purified Tim-3 was mixed with recombinant active Fyn (gifted 
from Dr. Smithgall, University of Pittsburgh) in kinase buffer (5mM morpholinepropanesulfonic 
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acid (MOPS), pH 7.2, 2.5mM glycerol 2-phosphate, 4mM MgCl2, 5mM MnCl2, 1mM EGTA, 
0.4mM EDTA, 0.25mm dithiothreitol(DTT), 20μM 32P-ATP (200 μCi/ml). Reactions were 
carried out at 30’C and terminated by adding 2X SDS sample buffer. Samples were separated by 
10% SDS-PAGE and blotted to PVDF. Integration of 
32
P-ATP was detected by autoradiograph, 
then, Tim-3 was probed by immunoblotting with anti-Tim-3 antibody. 
3.3 RESULTS 
3.3.1 The tyrosine residues in Tim-3 cytosolic tail interacts with SH2 domains of signaling 
molecules 
Having identified tyrosine residues involved in Tim-3 function and showing that they were 
available for phosphorylation, we hypothesized that signaling proteins containing SH2 domains 
are recruited to the phosphotyrosine sites of the Tim-3 cytosolic tail. To screen for signaling 
molecules interacting with phosphotyrosine in the cytosolic tail of Tim-3, we performed an SH2 
domain array experiment with two synthetic biotinylated peptides: a tyrosine phosphorylated 
peptide containing the conserved region with Y256 and Y263 (pY256/263 Tim-3 peptide), and 
one containing C-terminus region containing three Y271, Y272 and Y274 (pY271/272/274 Tim-
3 peptide) (Figure 13A and B).   
 The synthetic pY256/263 Tim-3 peptide strongly bound to SH2 domains of Fyn, the 
regulatory subunit of phosphoinositol-3 kinase (PI3K) p85α and p85β and RasGAP (N-term). 
The pY256/263 Tim-3 peptide also weakly interacted with SH2 domains of SFKs Hck, Yes, and 
with those of PLC-γ1, and the other SH2 domain of RasGAP (C-term).  The pY271/272/274 
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Tim-3 peptide strongly interacted with SH2 domains of Fyn, p85α, p85β, and PLC-γ1, and 
weakly interacted with SH2 domains from Abl, Hck, Yes, RasGAP, GRAP, and Grb2 (Figure 
13C and D, upper panels). When 10
6
 molar excess of phenylphosphate, an analogue of 
phosphorylated side chain of tyrosine, was incubated together with the phosphorylated Tim-3 
peptides to compete for phosphotyrosine specific interaction, interaction of the both synthetic 
Tim-3 peptides to most of the SH2 domains on the membrane was drastically blocked. In 
contrast to other SH2 domains, the Fyn SH2 domain interaction with the Tim-3 peptides 
remained strong in the presence of phenyl phosphate competition (Figure 13C and D, lower 
panels). This suggests that phosphorylation of tyrosine residues in the cytosolic tail of Tim-3 
mediates recruitment of signaling proteins to Tim-3 via SH2 domain, but that Fyn may interact 
with Tim-3 independently of tyrosine phosphorylation.  
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Figure 13.  SH2 domain binding to phosphorylated Tim-3 cytoplasmic tail peptides 
(A) Sequence of Tim-3 cytosolic tail and location of sequences corresponding to the synthetic Tim-3 peptides. (B) 
Layouts of the SH2 domain array. SH2 domains are present as duplicated spots. For proteins with more than one 
SH2 domain,“D1” indicates the more N-terminal SH2. (C, D) Sequence of the synthetic peptide used to determine 
the SH2 specificity of phospho-tyrosine residues and results of the SH2 domain array screen. Peptide binding to 
SH2 domains was detected by streptavidin-HRP. 
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3.3.2 Tim-3 is co-IP’d with p85 subunit of PI3kinase and Fyn 
According to the SH2 domain array experiment, the SH2 domains of Fyn and p85 interacted with 
both pY256/263 Tim-3 peptide and pY271/272/274 Tim-3 peptide. Next, we confirmed the 
interaction of Tim-3 with p85 and Fyn by co-IP. To test tyrosine phosphorylation dependent 
interaction of endogenous p85 and Tim-3, JHM1, a Jurkat variant expressing human muscarinic 
receptor1, cells transfected with WT Flag-Tim-3, Flag-Tim-3 Y256/263F (2YF), or T2 
truncation Tim-3 constructs were stimulated with pervanadate, to induce robust tyrosine 
phosphorylation. The WT and the mutant Tim-3 proteins were then IP’d with anti-Flag agarose. 
p85 bound to WT Tim-3, but p85 binding to 2YF or T2 Tim-3 protein was drastically diminished 
(Figure 14). These results indicate that p85 recruitment to the Tim-3 cytosolic tail is dependent 
on the phosphorylation of tyrosine residues in the cytosolic tail of Tim-3.  
 Fyn was the candidate whose SH2 domain on the array membrane most strongly 
interacted with Tim-3 phosphopeptides (Figure 13C and D). To confirm the Fyn interaction to 
Tim-3, WT Tim-3 or mutant Tim-3 was co-expressed with Fyn in 293T cells and co-IP’d Fyn 
was probed. Fyn associated with both WT and the 2YF mutant of Tim-3 to a similar extent, and 
induction of Tim-3 phosphorylation with pervanadate treatment did not detectably alter the Tim-
3-Fyn interaction (Figure 15B). I observed that tyrosine phosphorylation of Tim-3 was modestly 
upreguated upon TCR stimulation in Jurkat T cells (Figure 11C), so I decided to examine 
whether TCR stimulation can affect Fyn-Tim-3 interaction in Tim-3 expressing Jurkat T cells. 
Fyn constitutively interacted with Tim-3 in the resting state and there were no apparent changes 
in the Fyn-Tim-3 interaction after TCR stimulation or pervanadate treatment (Figure 15C). To 
determine the region of the Tim-3 cytosolic tail that interacts with Fyn, I performed co-IP 
experiment of Fyn with various Tim-3 deletion mutants. Thus, Fyn association with not only WT 
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but also T1 truncation Tim-3 indicates that Fyn binds to the conserved region of the cytosolic tail 
of Tim-3 containing Y256 and Y263. Unexpectedly, we also observed Fyn bound to the T2 
mutant of Tim-3 even though the T2 deletion construct does not have any known motif 
interacting with SFKs such as a tyrosine phosphorylation sites or a proline rich motif (Figure 
15D). Although T2 deletion constructs still has a single remaining tyrosine residue (Y219) in 
proximity to the predicted transmembrane domain, the residues was not conserved in other Tim 
family genes, or not predicted as a phosphorylation site. Thus, we assumed that the tyrosine 
residue is not functional for recruitment of SH2 domain, however, we cannot completely exclude 
the possibility that the tyrosine residue mediates the interaction with Fyn. Although Δ216-244 
Tim-3 construct efficiently bound to Fyn, whose function to upregulate NFAT/AP-1 luciferase 
reporter activity was impaired (Figure 8), this may suggest that the region located between 
transmembrane domain and the conserved region surrounding Y256 and Y263 is required to 
recruit downstream signaling molecules or maintain the functional structure of Tim-3.  
 
*Tim-3-p85 co-immunoprecipitation experiment was done by Ee Wern Su (Lawrence Kane’s 
Lab, University of Pittsburgh) 
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Figure 14. p85 was co-IP’d with Tim-3 
JHM1 cells were transfected with wild type or mutant Flag-tagged Tim-3 constructs. The cell were simulated with 
pervandate for 5min, Tim-3 proteins in the lysates were pulled down with anti-Flag-M2 agarose. The blot was 
probed with anti-p85. 
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Figure 15. Fyn co-IP’d with Tim-3 
(A) Schematic figure of Flag-Tim-3 constructs. (B) 293FT cells were transfected with either Tim-3 constructs or 
Fyn alone, or both, and stimulated with pervanadate. Flag-Tim-3 was pulled down with anti-Flag-M2 agarose. The 
blot was probed with anti-Fyn, and anti-Tim-3. (C) Parental Jurkat T cells or Tim-3 stably transfected Jurkat T cells 
were lysed and Tim-3 and endogenous Fyn were pulled down with anti-Flag-M2 agarose. (D) 293FT cells were 
transfected with Tim-3 constructs and Fyn. Flag-Tim-3 was pulled down with anti-Flag-M2 agarose. The blot was 
probed with anti-Fyn, and anti-Tim-3. 
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3.3.3 The Fyn SH2 domain interacts with both an un-phosphorylated and phosphorylated 
peptide of Tim-3 corresponding to region around Y256/Y263 
To better understand the mode of Tim-3-Fyn SH2 domain interaction, we decided to identify 
which amino acid residues in Fyn SH2 participate in the interaction with the region around Y256 
and Y263 in the cytosolic tail of Tim-3. We analyzed 
15
N HSQC spectrum of recombinant Fyn 
SH2 domain with phosphorylated or unphosphorylated Y256/Y263 Tim-3 peptide. The NMR 
spectroscopy revealed that residues surrounding the conserved pY binding pocket and variable 
pY
+
3 binding pocket of Fyn SH2 domain interacted with the phosphorylated Tim-3 peptides. The 
residues surrounding pY binding pocket of Fyn SH2 domain did not participate in the interaction 
with the unphosphorylated Tim-3 peptide, but still the residues surrounding the pY
+
3 binding 
pocket mediated interaction with the unphosphorylated peptide (Figure 16). Considering that pY 
pocket binding to phosphotyrosine is the primary force of the interaction mediated by SH2 
domain, this binding of unphosphorylated Tim-3 peptide to pY
+
3 binding pocket appears to be 
unique and may have implications for regulation of Tim-3 function by Fyn. 
 
*NMR analysis was done by Jagannathan Alagurajan (Amy Andreotti’s lab, Iowa State 
University) 
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Figure 16. Identification of amino acids in Fyn SH2 interacting with phosphorylated and un-
phosphorylated Tim-3 peptides 
(A) The 
15
N HSQC of the Fyn-SH2 alone(black) was compared to the in presence of un-phosphorylated(green) or 
phosphorylated peptides(red). The HSQC from each of the sample was overlaid to determine the peaks that show 
shift and thus determine the amino acids that interact with the peptides.  (B) List of amino acids in Fyn SH2 domain 
that interact with un-phosphorylated(green) and phosphorylated(red) Tim-3 peptide. (C) Surface mapping of amino 
acids in Fyn SH2 domain interacting with un-phosphorylated(red) and phosphorylate(green) Tim-3 peptides. 
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3.3.4 Fyn directly phosphorylates Tim-3 
I showed that tyrosine residues, especially Y256 and Y263, in the Tim-3 cytosolic tail are 
available for phosphorylation (Figure 11), and Y256 and Y263 were predicted as SFKs 
phosphorylation sites by the Scansite motif scan program (Figure 4). As shown in Figure 15, I 
demonstrated a physical interaction between Fyn and cytosolic tail of Tim-3. Therefore I decided 
to examine whether SFKs can phosphorylate tyrosine residues in the Tim-3 cytosolic tail. To test 
induction of tyrosine phosphorylation of Tim-3 by SFKs, I transfected 293T cells with full-
length WT Tim-3 alone or co-transfected with either Lck or Fyn, then treated with pervanadate. 
When Tim-3 alone was expressed in 293T cells, tyrosine phosphorylation induced by 
pervanadate treatment was detectable likely due to endogenous kinases in 293T cells. When 
Tim-3 was co-expressed with Lck, both basal and pervandate-induced phosphorylation level 
were significantly increased. Similarly, co-expression of Fyn upregulated tyrosine 
phosphorylation of Tim-3. However, there was a more profound increase in basal 
phosphorylation by Fyn compared to basal phosphorylation in the presence of Lck. These results 
suggest that SFKs Lck and Fyn can induce tyrosine phosphorylation of Tim-3, but that Fyn may 
be more efficient in phosphorylation of Tim-3, compared with Lck (Figure 17A).  
Next, I tested whether Fyn kinase can directly phosphorylate tyrosine residues of Tim-3 
by performing in vitro kinase assay. IP’d WT Tim-3 and a Tim-3 mutant with all 5 tyrosine 
residue mutated to phenylalanine (5YF) were incubated with purified active Fyn. WT Tim-3 was 
efficiently phosphorylated by Fyn, while 5YF Tim-3 was not phosphorylated (Figure 17B). In 
vitro kinase assay using the T1 Tim-3 construct with or without point mutation of Y256 and 
Y263 (T1 and T1:2YF) showed that T1 Tim-3, but not T1:2YF, was phosphorylated by Fyn 
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(Figure 17C). These results provide direct evidence that Fyn able to directly phosphorylate Tim-
3 at Y256 or Y263, or both.  
 
*The purified active Fyn kinase used for in vitro kinase assay was provided by Jamie A. Moroco 
(Thomas Smithgall’s lab, University of Pittsburgh) 
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Figure 17.  Fyn directly phosphorylated Tim-3 
(A) 293T cells were transfected with Flag-tagged wild type Tim-3 or mutant constructs. Flag-mTim-3 protein was 
IP’d with anti-Flag M2-agarose and blotted with mTim-3 antibody.  The blot was stripped and reprobed with anti-
phosphotyrosine 4G10 antibody(B,C) wild type or Tim-3 mutant ectopically expressed in 293FT cells were pulled 
down with anti-Flag-M2 agarose bead and eluted with Flag-peptide. The eluted Tim-3 proteins were incubated with 
purified active Fyn and 
32
P-γ-ATP. Phosphorylation was detected by autoradiography (top panel) and wild type and  
mutant Tim-3 were probed with anti-Tim-3(bottom panel) (5YF: Y256/263/271/272/274F mutant) 
3.4 DISCUSSION 
SH2 domains are protein  modules specialized in recognizing phosphorylated tyrosine residues. 
Conventional SH2 domains have a conserved pY interacting pocket and a variable pY
+
3 
interacting pocket conferring substrate specificity [182]. Here we identified signaling molecules 
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interacting with the Tim-3 cytosolic tail in a tyrosine phosphorylation-dependent manner. An 
SH2 domain array revealed that signaling molecules involved in TCR signaling, such as p85 
PI3K, PLC-γ, and RasGAP may be recruited to the cytosolic tail of Tim-3 via their SH2 domains 
upon tyrosine phosphorylation of Tim-3. In particular, we demonstrated tyrosine 
phosphorylation-dependent co-immunoprecipitation of p85 with Tim-3 in Jurkat T cells.  
We also found binding of SH2 domain of Fyn to the cytosolic tail of Tim-3. Unlike other 
candidate molecules we identified from the SH2 domain array, the Fyn interaction occurs in a 
tyrosine phosphorylation-independent manner. Fyn interaction with the phospho-Tim-3 peptides 
was not efficiently inhibited by excess phenylphosphate and mutation of Y256 and Y263 did not 
disrupt the Fyn interaction with Tim-3. In addition, NMR spectroscopy revealed that the Fyn 
SH2 domain can interact with the unphosphorylated Tim-3 peptide via the SH2 pY
+
3 binding 
pocket. Therefore, I suggest a model whereby Fyn constitutively interacts with, and 
phosphorylates, tyrosine residue(s) in the cytosolic tail of Tim-3, to induce the recruitment of 
p85 to Tim-3. A similar mode of signal transduction was reported previously. Thus, Fyn bound 
to Cbl via both SH2 and SH3 domains of Fyn but independently of tyrosine phosphorylation, 
leading to Fyn-mediated tyrosine phosphorylation of Cbl, to which p85 was recruited [184].   
I demonstrated that both Y256 and Y263 of the Tim-3 cytosolic tail are available for 
tyrosine phosphorylation, and that Fyn phosphorylates Y256 and/or Y263 of the Tim-3 cytosolic 
tail. There could be several possible mechanisms for this Tim-3 phosphorylation by Fyn. As Fyn 
binds to several region of the Tim-3, Fyn may interact with one motif in the Tim-3 cytosolic tail 
then phosphorylate tyrosine residues in the same Tim-3 molecule (cis-phosphorylation). 
However, efficient phosphorylation of the T1 Tim-3 mutant construct (Figure 11) implies that 
the C-terminal region containing Y271/272/274 may be dispensable for recruiting Fyn to induce 
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phosphorylation of Y563/Y263. As shown in Figure 15D, the Fyn SH domain binds to the region 
between the transmembrane domain and the conserved region near Y256 and Y263, deletion of 
the region (Δ216-244) abolished Tim-3 function (Figure 8). However, which domains of Fyn and 
the specific motifs in the Tim-3 cytosolic tail are involved in this interaction were not determined 
yet, or whether the functional impairment of the Δ216-244 construct was caused by impairment 
of the Fyn interaction or general disruption of Tim-3 structure.  
Since Fyn interaction with the region near Y256/263 of the Tim-3 cytosolic tail seemed 
stable and the Fyn SH2 domain bound to both phosphorylated and unphosphorylated peptide of 
the corresponding sequence, Fyn may bind to unphosphorylated Y256/Y263 residues of Tim-3 
and phosphorylate tyrosine residues in the adjacent Tim-3 molecule (trans-phosphorylation). 
Precisely, which unphosphorylated or phosphorylated tyrosine residues among Y256 and Y263 
participate in the interaction with Fyn SH2 domain was not identified yet. To address this, co-
immunoprecipitation and functional assays with more fine deletion and mutational analyses of 
Tim-3 cytosolic tail and a fine structural study of the Fyn SH2 domain-Tim-3 complex are 
required. 
Another remaining question regarding the Fyn-Tim-3 interaction is whether this 
interaction regulates Fyn kinase activity. It is possible that Fyn binding to unphosphorylated or 
phosphotyrosine of Tim-3 leads to conformational change of Fyn to enhance its kinase activity. 
Alternatively, Tim-3 may regulate the localization of Fyn and thus access to substrates. Although 
I did not provide evidence of direct phosphorylation, Lck co-expression also induced 
phosphorylation of Tim-3. In addition, van de Weyer et al. reported that co-expression of Itk 
phosphorylates Y265 of human Tim-3 (corresponding to Y256 in murine Tim-3) in 293T cells. 
Therefore, it is possible that other kinases positively or negatively regulate Tim-3 function by 
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phosphorylation. The role of these kinases in Tim-3 function, specific target sites of the kinase, 
and the stoichiometry of phosphorylation have not been determined. 
RasGAP is one of the interesting candidates identified in an SH2 domain array 
experiment. Although RasGAP1 is an inhibitory regulator of the Ras-MAP kinase pathway, it at 
has a positive role in T cell activation independent of Ras-MAP kinase pathway. In cardiac 
myocytes, RasGAP1 bound to the PH1 domain of Akt and knockdown of RasGAP1 resulted in 
inhibition of Akt phosphorylation [185].  Lapinski et al demonstrated that RasGAP1 was 
negative regulator in ERK pathway in thymocytes during positive selection, but a positive 
regulator in homeostasis of naïve T cells in periphery but dispensable for ERK activation [186].  
Tim-3 is known as an inhibitory receptor, however, our data show that Tim-3 upregulates T cell 
activation, at least during the short-term stimulation. Thus, RasGAP may be the interesting 
candidate which can mediate inhibitory and activation function depending on the different 
cellular context.  
In this study I focused mainly on proteins binding to the conserved Tim-3 region with 
Y256 and Y263, which seems to have an important role in regulation of TCR signaling. 
However, binding of signaling molecules to the C-terminus of Tim-3, containing Y271/272/274, 
was not extensively studied. As shown in Figure 13, I found that the pY271/272/274 Tim-3 
peptide, but not the pY256/263 peptide, interacted the with SH2 domains of two adaptor proteins, 
GRAP and Grb2, which couple tyrosine phosphorylation to the Ras-MAP kinase pathway. In the 
previous chapter, I proposed the role of C-terminus region containing three terminal tyrosine 
residues in the activation of MAP kinase pathway and AP-1 transcription factor (Figure 9C and 
D). Thus, GRAP and Grb2 may be responsible for the signaling from this domain of Tim-3 
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4.0  TIM-3 DOWNSTREAM SIGNALING AND MODULATION OF TCR 
SIGNALING 
4.1 INTRODUCTION 
During short-term immune stimulation, such as acute viral infection, antigen-specific naïve CD8 
T cells develop effector T cells producing effector cytokines and cytolytic molecules. When the 
source of the antigen is cleared acutely, the subsets of antigen-specific T cells remain as memory 
T cells. However, under the immune conditions become chronic, such as chronic viral, bacterial 
and parasitic infection, and tumor, CD8 T cells gradually lose their effector function and the 
potential to proliferate and to form memory subsets. It appeared that surface expression of 
inhibitory receptors such as PD-1, LAG-3 and CTLA-4 are involved in the functional loss in T 
cells.  
Recently, role of Tim-3 in T cell exhaustion has been suggested. In the various chronic 
infections such as HIV, HCV and LCMV, [47, 115, 116, 187] and in the tumor tissue[49, 188], 
upregulation of Tim-3 expression in antigen-specific T cells and positive correlation between 
Tim-3 expression and dysfunctional phenotype of T cells were found. T cells expressing both 
PD-1 and Tim-3 showed more severe loss of effector function compared to the T cells expressing 
PD-1 or Tim-3 alone. In addition, blockade of PD-1 and Tim-3 restore the exhausted T cell 
function synergistically [47, 49, 188].  
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Because of the synergy of Tim-3 and PD-1, it has been assumed that Tim-3 also transmits 
an inhibitory signal to T cells. However, the elements of Tim-3 signaling were not known. In the 
previous chapters I showed that Tim-3 upregulated activation of transcription factors 
downstream of TCR in T cell lines, and that Tim-3 interacts with Fyn and PI3 kinase. In this 
chapter, I further explore the signaling pathways downstream of Tim-3. Thus I will examine the 
requirement for TCR-the proximal signaling molecules in the function of Tim-3, and determine 
whether Tim-3 enhances or inhibits the activation of signaling molecules downstream of TCR 
and PI3 kinase.  
MATERIALS AND METHODS 
4.1.1 Cell lines and cell culture 
Jurkat T cells and Jurkat variants were cultured in RPMI-1640 (Mediatech) supplemented with 
5% bovine growth serum (BGS, Hyclone) and 100U/ml penicillin, 100μg/ml streptomycin. 
Murine primary T cells were cultured in RPMI-1640 (Mediatech) supplemented with 10% BGS, 
100U IL-2, 100U/ml penicillin, 100μg/ml streptomycin, non-essential amino acid, 1mM sodium 
pyruvate, 55μM 2-mercaptoechanol (Life sciences), and 10mM HEPES (Fisher). Tet-on Tim-3 
Jurkat T cells were maintained in 0.8μg/ml puromycin, and Tim-3 expression was induced with 
1.5μg/ml doxycycline for 2 days. 
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4.1.2 Antibodies and reagents 
C305 antibody to Jurkat TCR was obtained from Dr. Arthur Weiss (UCSF, CA), anti-human 
CD28 (10F3),  Anti-mouse CD3 (37.51), and anti-mouse CD28 (2C11) were from Life Sciences. 
Anti-Flag M2 antibody and β-actin antibody were from Sigma Aldrich, polyclonal anti-mouse 
Tim-3 antibody was from R&D systems. Anti-PLC-γ1 was from Millipore and phospho-PLC-γ 
(pY783) antibody was from BD bioscience. ZAP-70, phospho-ZAP-70 (Y319), Alexa647 
conjugated phospho-S6 (S235/S246) antibodies were from Cell Signaling.  Alex647 conjugated 
ERK (T202/Y204), p38 (T180/182), and JNK (T183/185) were from BD bioscience. HRP 
conjugated goat anti-mouse antibody and donkey anti-goat antibody were from Thermo scientific 
and Jackson Immunoresearch respectively. PMA and ionomycin were from Calbiochem and D-
luciferin was from Thermo Scientific. 
4.1.3 Luciferase reporter assay 
2x10
6
 Jurkat and Jurkat variants were transfected with 15ug of NFAT/AP-1, NF-κB, NFAT, or 
AP-1-luciferase reporter, and Tim-3 constructs by electroporation at 260V/950μF (Jurkat). The 
day after transfection, 5x10
5
 cells were stimulated with anti-human TCR (C305)/CD28 
antibodies for six hours in round bottom 96 well plates. After a freezing and thawing cycle, 
luciferase assay was performed in 5mM ATP, 10mM MgCl2, and 1mM D-luciferin using 
luminometer (Berthold) 
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4.1.4 Western blotting 
Tet-on Tim-3 Jurkat T cells were incubated with or without 1.5μg/ml doxycycline for 2 days. 
Tet-on Tim-3 Jurkat T cells were pervanadate or monoclonal antibody specific for Jurkat TCR 
(C305.2), then lysed with ice-cold 1% NP-40 lysis buffer (20mM Tris-HCl, pH 7.5, 150mM 
NaCl) supplemented with AEBSF, aprotinin, leupeptin, pepstatin, sodium fluoride, sodium 
orthovanadate, and β-glycerophosphate. Lysates were then incubated on ice for 10 min before 
being cleared by centrifugation. 6X Sample buffer (Bio-Rad, Hercules, CA) was added to the 
cleared lysates before loading onto 10% SDS-PAGE gels. Proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes, probed with anti-PLC-γ1, anti-phospho-PLC-γ, 
anti-ZAP-70, or anti-phospho-ZAP-70 antibodies. Then, the binding of the primary antibodies 
detected with HRP conjugated anti-mouse or anti-rabbit antibody. Blots were imaged on a Kodak 
ImageStation 4000R system.  
4.1.5 Flow cytometry and ELISA 
Tet-inducible Tim-3 Jurkat T cells were induced for 2 days with doxycycline and then stimulated 
with TCR antibody or PMA/ionomycin. For intracellular phospho-flow analysis, cells were fixed 
in PFA immediately after stimulation for the appropriate times and permeabilized with methanol, 
then processed for staining with antibody specific for phospho-ERK, phospho-p38, phospho-
JNK or phospho-S6. All flow cytometry was carried out on a BD LSR II instrument. Data were 
exported and analyzed in the FlowJo software program (Treestar, Ashland, OR). For IL-2 ELISA, 
cells were stimulated for 24 h with anti-TCR/CD28 antibodies or PMA/ionomycin. Cell-free 
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supernatants were analyzed by ELISA for human IL-2, using OptEIA matched antibodies (BD 
Bioscience). 
4.1.6 Retroviral infection 
Purified murine CD4 T cells were stimulated under Th1 conditions and infected with 
recombinant MSCV retroviruses expressing the indicated constructs, essentially as previously 
reported [189]. Infected T cells were then restimulated, again under Th1 conditions, followed by 
intracellular cytokine staining 2 days later for IFN-γ. 
4.2 RESULTS 
4.2.1 Proximal TCR signaling molecules are required for enhancement of NFAT/AP-1 and 
NF-κB reporter activity by Tim-3 
Tim-3 expression augmented basal NFAT/AP-1 and NF-κB activation, but the extent was more 
profound in the presence of TCR stimulation (Chapter 2.0 ). Therefore I decided to investigate 
the requirement of TCR-proximal signaling molecules involving in the TCR signaling in the 
Tim-3 signaling. I took advantage of ZAP-70 deficient (P116) and SLP-76 deficient (J.14) Jurkat 
T cell lines, which display severe defects in TCR signaling [190, 191].  Expression of Tim-3 in 
ZAP-70 deficient Jurkat cells resulted in moderately increased basal NFAT/AP-1 reporter 
activity, and TCR/CD28 stimulation could not induce further enhancement of the reporter 
activity, as was seen in wild type Jurkat T cells. When the ZAP-70 mutant Jurkat T cells were 
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reconstituted with wild type ZAP-70, the extent of basal upregulation by Tim-3 expression was 
enhanced compared to ZAP-70 mutant Jurkat T cells. Distinct enhancement of the reporter 
activity by Tim-3 expression in the presence of TCR/CD28 stimulation was not observed in the 
ZAP-70 reconstituted mutant cells due to hyperresponsiveness of the reconstituted cells to 
TCR/CD28 stimulation (Figure 18A). In SLP-76 deficient cells Tim-3 expression modestly 
upregulated basal NFAT/AP-1 reporter activity, similar to ZAP-70 deficient Jurkat T cells, the 
reporter activity was not further enhanced by TCR/CD28 stimulation. Tim-3 expression in 
mutant Jurkat T cells reconstituted with SLP-76 led to a moderate increase in basal NFAT/AP-1 
reporter activity and further upregulation of the activity upon TCR/CD28 stimulation, as shown 
in parental Jurkat T cells (Figure 18B). These results suggest that TCR signaling is required for 
full functionality of Tim-3 in upregulation of T cell activation, and that Tim-3 may converges 
with TCR signaling at the downstream of ZAP-70 and SLP-76.  
In the previous chapter, I demonstrated that SFK, especially Fyn, induces tyrosine 
phosphorylation of Tim-3. Thus I assessed the role of SFKs in Tim-3 function to upregulate T 
cell activation using of an Lck-deficient Jurkat T cell line (JCaM.1) [192].  Although TCR 
signaling was severely abolished in the Lck deficient Jurkat T cells, Tim-3 expression could still 
weakly upregulate NFAT/AP-1 reporter activity in synergy with TCR/CD28 stimulation. Fyn 
might compensate for the loss of Lck in TCR signaling and mediate Tim-3 signaling in the Lck-
deficient cells. Lck co-transfection restored the function of Tim-3 to upregulate TCR signaling to 
the level of wild type Jurkat T cells, while Fyn co-transfection led to only a slight increase in 
Tim-3 function (Figure 18C). This could be due to the fact that Fyn was already abundant in the 
Lck deficient Jurkat. 
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Figure 18. Requirement of ZAP-70, SLP-76 and Lck in Tim-3 signaling 
Jurkat T-cell lines lacking expression of either ZAP-70 (A) or SLP-76 (B) and stably reconstituted mutant cells were 
transfected with NFAT/AP-1-luciferase and the indicated constructs. The next day, cells were left unstimulated 
(white bars) or stimulated with anti-TCR/CD28 monoclonal antibodies (mAbs) (black bars).  
(C) Lck deficient Jurkat T-cell lines were transfected with NFAT/AP-1-luciferase reporter and indicated constructs, 
and analyzed as above. Luciferase activity is presented as the percentage of maximal stimulation obtained with 
PMA-ionomycin. Luciferase activity is presented as the percentage of the maximal response obtained with PMA 
plus ionomycin. Results shown are the average and SD of data for triplicate samples from a single experiment, 
representative of at least three that were performed in each case. ). Average results (± SD) from triplicates are shown 
(*, P<0.05; **, P<0.01; ***, P<0.01) 
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4.2.2 Ectopic expression of Tim-3 enhances activation of PLC-γ 
To determine whether expression of Tim-3 modulates TCR signaling, I examined differential 
induction of tyrosine phosphorylation upon TCR crosslinking in the presence and absence of 
Tim-3 expression in Jurkat T cells. I took advantage of Jurkat T cells stably transfected with 
reverse tetracycline-controlled transactivator (rtTA) and Tet-on inducible construct encoding 
Flag-tagged full-length Tim-3 (Tet-on Tim-3 Jurkat). Tim-3 expression in Tet-on Tim-3 Jurkat T 
cells was induced with doxycycline prior to TCR stimulation. The stimulated cells were lysed 
and subjected to western blotting, then probed with phosphotyrosine specific antibody. I 
observed that when Tim-3 was expressed, TCR-induced tyrosine phosphorylation of 70kDa and 
150kDa proteins were enhanced (Figure 19). I speculated that these 70kDa and 150kDa proteins 
were ZAP-70 and PLC-γ1, respectively, which are proximal signaling molecules downstream of 
the TCR.  
To test the hypothesis, again I took advantage of Tet-on Tim-3 Jurkat T cells and Jurkat T 
cells expressing the rtTA only but not Tet-on inducible Tim-3 construct (rtTA Jurkat) and 
performed western blotting to examine the tyrosine phosphorylation of PLC-γ1 and ZAP-70 
using phospho-specific antibodies. Without stimulation, there was no difference in the level of 
PLC-γ1 phosphorylation (Y783) between doxycycline treated and non-treated Tet-on Tim-3 
Jurkat T cells. However, I observed enhanced and sustained phosphorylation of PLC-γ1 induced 
by TCR in the Tet-on Tim-3 Jurkat T cells treated with doxycycline compared to the cells not 
treated (Figure 20, upper panels). As expected, I did not observe any difference in the level of 
PLC-γ1 phosphorylation between doxycycline-treated and non-treated rtTA Jurkat T cells 
(Figure 20, lower panels). In the same way, I examined tyrosine phosphorylation of ZAP-70 
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(Y319). I did not observe a significant Tim-3 dependent enhancement of ZAP-70 
phosphorylation in Tet-on Tim-3 Jurkat T cells vs. rtTA Jurkat T cells (Figure 21).  
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Figure 19. Differential induction of tyrosine phosphorylation in presence of Tim-3 expression 
Tet-on Tim-3 Jurkat T cells were treated with doxycycline or left untreated, each cells were stimulated with anti-
TCR/CD28 antibodies or pervanadate for indicated times. Whole cell lysates were subjected to SDS-PAGE and 
western blotting, and the membrane was probed with anti-phosphotyrosine antibody. 
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Figure 20. Upregulation of PLC-γ1 activation by Tim-3 
Tet-on-Tim3 or parental Jurkat T cells expressing only the reverse tetracycline transactivator (rtTA) were cultured 
for 2 days without or with doxycycline (Dox). Cells were stimulated as indicated for analysis of phospho-PLC-γ1 
(Y783) by Western blotting, followed by probing for beta-actin as a loading control (left). Average results and SD 
from five separate experiments are shown (*, P <0.05; **, P<0.01) 
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Figure 21. No effect on ZAP-70 phosphorylation by Tim-3 expression  
Tet-on-Tim3 or parental Jurkat T cells expressing only the reverse tetracycline transactivator (rtTA) were cultured 
for 2 days without or with doxycycline (Dox). Cells were stimulated as indicated for analysis of phospho-ZAP-70 
(Y319) by Western blotting, followed by probing for beta-actin as a loading control (left). Average results and SD 
from five separate experiments are shown  
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4.2.3 Ectopic expression of Tim-3 enhances activation of MAP kinases 
MAP kinase pathway is one of the major downstream pathways of TCR signaling and upstream 
of AP-1 transcription factor. In addition, we found NFAT/AP-1 and AP-1 reporter activity in 
Jurkat were enhanced by ectopic expression of Tim-3. To determine whether Tim-3 modulated 
MAP kinase pathway, I assessed phosphorylation of MAP kinases in Tet-on Tim-3 Jurkat T cells.  
I stimulated doxycycline treated and non-treated Tet-on Jurkat T cells with anti-TCR, then 
stained the cells with phospho-specific ERK, p38 and JNK antibody and analyzed by flow 
cytometry. Note that in Tet-on Tim-3 Jurkat T cells, co-expression of GFP and Tim-3 is driven 
by a bi-directional promoter upon doxycycline treatment. As the Tet-on Tim-3 Jurkat T cells 
contained both doxycycline-responsive and unresponsive populations, I separately analyzed Tim-
3 expressing cells and non-expressing cell by gating the cells based on the level of co-expressed 
GFP.  
As shown Figure 22,  TCR-induced phosphorylation of ERK, p38 and JNK were 
enhanced in the Tim-3 expressing cells (Dox treated/GFP
hi
 cells) compared to the cells not 
expressing Tim-3 (Dox non-treated cells and Dox treated/GFP
lo
 cells), while basal 
phosphorylation of ERK, p38 and JNK (i.e. without TCR stimulation) were not significantly 
upregulated by Tim-3 expression. The upregulation of ERK phosphorylation was only seen with 
TCR stimulation, but not without TCR stimulation, while upregulation of AP-1 reporter activity 
by Tim-3 expression was independent of TCR stimulation.  
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Figure 22. Tim-3 expression enhances phosphorylation of MAP kinases. 
Tet-on-Tim3 Jurkat T cells were cultured for two days without or with doxycycline. Cells were then stimulated as 
indicated and processed for intracellular staining of phospho-ERK(A), phospho-p38(B), and phospho-JNK(C). (D) 
Graphical representation of MFI of each staining (*** P<0.005) 
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4.2.4 Ectopic expression of Tim-3 enhances phosphorylation of ribosomal protein S6 
We demonstrated that p85 interacted with Tim-3 in a tyrosine phosphorylation dependent as well 
as upregulation of ERK activation manner by Tim-3 expression. Then we proceeded to 
investigate the modulation of further downstream target of the pathways by Tim-3 using Tet-on 
Tim-3 Jurkat T cells. Ribosomal protein S6 is regulated by p70S6 kinase and p90S6 kinase, 
which are downstream of PI3 kinase pathway and MAP kinase pathway, respectively. The 
frequency of pS6
hi
 cells was greater in the Tim-3 expressing cells (Dox treated/GFP
hi
 cells) than 
in the non-expressing cell (Dox non-treated and Dox treated/GFP
lo
 cells) when the cells were 
stimulated with an optimal dose of anti-TCR (Figure 23, upper panels). However, when the cells 
were stimulated with a suboptimal dose of anti-TCR, induction of S6 phosphorylation was 
minimal in the Tim-3-absent cells and the augmentation of S6 phosphorylation in the Tim-3 
expressing cells was more dramatic (Figure 23, lower panels).  
Then, I examined the contribution of Akt and MAP kinase pathway to the upregulation of 
phosphorylation of S6 by Tim-3 expression, using Akt inhibitor (Akti) and MEK inhibitor 
(U0126). Akt inhibitor partially inhibited the upregulation of S6 phosphorylation in Tim-3 
expressing Tet-on Tim-3 Jurkat T cells (Dox treated/GFP
hi
 cells). MEK inhibited more potently 
than Akti did, but not completely to the basal level in the unstimulated cells without Tim-3 
expression (Dox non-treated) (Figure 24). These data suggest that both Akt and MAP kinase 
pathway, at least partially, mediate Tim-3 signaling to upregulate S6 phosphorylation in Tet-on 
Tim-3 Jurkat T cells.  
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Figure 23. Ectopic expression of Tim-3 enhances pS6 phosphorylation induced by TCR signaling. 
Tet-on-Tim3 Jurkat T cells were cultured for two days without or with doxycycline. Cells were then stimulated as 
indicated and processed for intracellular staining of phospho-S6 
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Figure 24. MAP kinase and Akt pathways mediate the enhancement of S6 phosphorylation by Tim-3 
expression 
Tet-on-Tim3 Jurkat T cells were cultured for two days without or with doxycycline. Cells were pretreated with the 
indicated inhibitors for 30min, and stimulated with anti-TCR antibody. Then processed for intracellular staining of 
phospho-S6 
 
4.2.5 Tim-3 expression upregulated IL-2 and IFN-γ production 
Next, we tested whether Tim-3 could upregulate IL-2 production in T cells. We incubated Tet-on 
Tim-3 Jurkat T cells and rtTA Jurkat T cells in the various dose of doxycycline to induce various 
amount of Tim-3 expression in Tet-on Tim-3 Jurkat. We then stimulated the cells with a 
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suboptimal dose of anti-TCR antibody and measured IL-2 production by ELISA. This 
doxycycline treatment induced expression of Tim-3 in Tet-on Tim-3 Jurkat T cells in a dose-
dependent manner (Figure 25A), and IL-2 production was also upregulated in Tet-on Tim-3 
Jurkat T cells, which correlated with Tim-3 expression level in the cells. In contrast with Tet-on 
Tim-3 Jurkat, doxycycline treatment did not induce IL-2 production in control rtTA Jurkat T 
cells, confirming that upregulation of IL-2 is Tim-3 dependent (Figure 25B).  
Next we examined the effect of Tim-3 expression on IFN-γ production in primary CD4 T 
cells. Murine CD4 T cells were isolated from lymph nodes, activated under Th1 differentiation 
conditions, and infected with a retrovirus encoding full-length, T1, and T2 deletion of Tim-3. 
IFN-γ production upon restimulation with anti-CD3/CD28 was determined by intracellular 
cytokine staining. As show in Figure 26A and B, IFN-γ production was greatly increased in the 
CD4 T cells expressing full-length Tim-3 and even more in the CD4 cells expressing the T1 
deletion, while this increase of IFN-γ production was not observed in T2 Tim-3 expressing CD4 
T cells (Figure 26B).  
I examine whether expression of Tim-3 suppresses the growth of the Tet-on Tim-3 Jurkat 
T cells. I treated Tet-on Tim-3 Jurkat T cells and rtTA parental Jurkat T cells with doxycycline 
or left untreated, and counted the number of the cells. The cell number was lower in Dox treated 
Tet-on Tim-3 Jurkat T cells compared untreated Tet-on Tim-3 Jurkat cells. However, we 
observed same trend from rtTA parental Jukat T cells. Thus, decreased in growth is at least 
partially due to off-target effect by doxycycline. High dose of doxycycline treatment suppressed 
Jurkat growth (>5μg/ml) and induces apoptosis (>10μg/ml) [193]. At the concentration we used 
to induce Tim-3 expression (1.5μg/ml), treatment of doxycycline did not affect growth of Jurkat 
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T cells for 4 days, but seemed to suppress the growth in the long-term. However, I did not further 
analyzed whether the cause is suppression of proliferation or induction of apoptosis. 
 
*IL-2 ELISA was performed by Ee W. Su (Lawrence Kane’s Lab, University of Pittsburgh) and 
IFN-γ intracellular staining experiment was done by  Chen Zhu (Vijay Kuchroo’s Lab, BWH, 
Harvard Medical School), respectively. 
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Figure 25. Upregulation of IL-2 production by Tim-3 expression 
(A) Tet-on-Tim3 Jurkat T cells were cultured with the indicated concentrations of doxycycline and analyzed by flow 
cytometry for Tim-3 expression (x axis) and a co-expressed GFP reporter (y axis).  
(B) Tet-on-Tim3 or parental Jurkat T cells, or the parental Tet-on cells, were then stimulated for 24 hours with 
soluble anti-TCR/CD28 antibodies. Cell-free supernatants were harvested and secreted IL-2 was measured by 
ELISA. IL-2 production is presented as the percentage of the maximal response, obtained with PMA plus ionomycin. 
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Figure 26. Upregulation of IFN-γ by Tim-3 in primary CD4 T cells 
Naive murine CD4
+
 T cells were stimulated with anti-CD3/CD28 antibodies under Th1 conditions and then infected 
With retrovirus encoding the indicated constructs and restimulated with the indicated concentrations of soluble anti-
CD3 antibody, again under Th1 conditions. Two days later, cells were processed for intracellular cytokine staining 
and flow cytometry. (A) Representative flow cytometry of intracellular IFN-γ  and retroviral coexpressed GFP. (B 
and C) T cells were restimulated with the indicated concentrations of anti-CD3, and supernatant was collected for 
determination of IFN-γ concentrations by ELISA. 
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Figure 27. Inhibition of growth of Tet-on Tim-3 Jurkat cell by induction of Tim-3 expression was not 
found. 
Tet-on Tim-3 Jurkat cells and parental rtTA Jurkat T cells were maintained in 0.8μg/ml puromycin and with or 
without 1ug/ml doxycycline. Every 48hrs, the number of the cells were counted and diluted at 0.3x10
6
cells/ml.  
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4.3 DISCUSSION 
Here we first demonstrated that Tim-3 signaling enhances T cell activation by TCR signaling. In 
Chapte 2.0 , we demonstrated that Tim-3 can enhance the activity of major transcription factors 
such as NFAT/AP-1,NF-κB, AP-1 in Jurkat T cell lines and non-transformed D10 T cells. As we 
found that Y256 and Y263 are crucial for the positive function of Tim-3, we searched for the 
signaling molecules interacting with the cytosolic tail of Tim-3 near Y256 and Y263. While p85 
interacted with Tim-3 in a Y256 and Y263 phsphorylation-dependent manner, Fyn interacted 
with Tim-3 in a Y256 and Y263 phosphorylation-independent manner. Moreover, Fyn could 
directly phosphorylate tyrosine residues of Tim-3. I also found Tim-3 upregulated AP-1 reporter 
activity independently of TCR stimulation and SH2 domain of GRAP and Grb2 on the array 
interacted with tyrosine phosphorylated peptide corresponding to C-terminus of Tim-3.Therefore, 
I hypothesize a model whereby Fyn phosphorylates Tim-3, in turn p85 is recruited to 
phosphotyrosines in the Tim-3 cytosolic tail to activate the PI3L-Akt pathway and that GRAP or 
Grb2 is recruited to the C-terminus of Tim-3 to activate MAP kinase pathways (Figure 28). 
Since Tim-3 expression enhanced both NFAT/AP-1 reporter and NF-κB reporter activity 
induced by TCR stimulation, I speculate that Tim-3 signaling intersects TCR signaling at a place 
upstream of both NFAT and NF-κB pathways. I found the requirement of the common upstream 
signaling molecules Lck, ZAP-70, and SLP-76 for the upregulation of TCR stimulation-induced 
NFAT/AP-1 and NF-κB activation by Tim-3 ectopic expression. Indeed I found that the 
activation of PLC-γ, a common upstream of NFAT, AP-1, and NF-κB, was enhanced in Tim-3 
expressing Tet-on Tim-3 Jurkat. I hypothesized that 70kDa protein whose phosphorylation by 
TCR stimulation was augmented in the Jurkat T cells expressing Tim-3 was ZAP-70, I examined 
the Y319 phosphorylation of ZAP70 only, which plays critical role in ZAP-70 catalytic activity 
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[140].  Although I did not observe the significant changes in Y319 phosphorylation of ZAP70 by 
Tim-3 expression, I cannot rule out the possibility that Tim-3 regulates the phosphorylation of 
other tyrosine residues in ZAP-70. ZAP-70 has other tyrosine phosphorylation sites. For example, 
phosphorylation of Y315 and Y493 regulate catalytic activity of ZAP70 [194] and recruitment of 
ZAP-70 to TCR [194], respectively.  
Although we revealed that Tim-3 expression could upregulate TCR signaling, the 
mechanism how Tim-3 potentiates TCR signaling, specifically PLC-γ phosphorylation is unclear. 
I suspect that Fyn is at least partially responsible for Tim-3 enhancement of TCR signaling. Fyn 
is a TCR-proximal signaling molecule along with Lck, which phosphorylates ZAP-70, and in 
vitro Fyn can also directly phosphorylate PLC-γ1 [195]. Interestingly, it has also been shown that 
Fyn is able to regulate MAP kinase pathways both directly and indirectly. Thus, Fyn activates 
autokinase activity of Raf-1 in NIH 3T3 cells [196], and increases the magnitude of ERK signal 
through a pathway different from Lck [197]. In the previous chapter I discussed the possibility 
that Tim-3-Fyn interaction changes conformation of Fyn to primed status. However, I found that 
Fyn constitutively interacted with Tim-3, suggesting there is another regulatory mechanism. 
Note that, Up to ~50% of Lck were in primed and ~40% were active status in human CD4 T 
cells [198]. Lck constitutively interact with CD4 and CD8, and the co-localization with the co-
receptors are thought as one of the mechanism that initiates TCR signaling [133, 134]. Similarly, 
Fyn mediated positive effect may be regulated by localization or higher-order organization of 
Tim-3 during TCR stimulation. Therefore, imaging the localization of Tim-3 during TCR 
stimulation or Tim-3 ligation would be a useful experiment to unravel the mechanism of Tim-3 
signaling transduction. Alternatively, Fyn-Tim-3 may constitutively induce moderate activation 
lowering the threshold of TCR signaling.  
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AP-1 is a transcription factor consisting of c-Jun and c-Fos, whose activation and 
expression are regulated by MAP kinase pathway. I showed that Tim-3 expression enhances 
activation of Erk, p38 and JNK by flow cytometry, and AP-1 activation by reporter assay. The 
upregulation of pErk, p38 and JNK was detected only with TCR stimulation, while upregulation 
of AP-1 reporter activity was TCR stimulation independent, as shown in Figure 9C and D. This 
discrepancy may be due to involvement other factors to activate AP-1 other than MAP kinases or 
higher sensitivity of the luciferase reporter assay than flow cytometry.  
Tim-3 expression upregulated phosphorylation of S6 which is regulated by both MAP 
kinase pathway and PI3K-Akt pathway, I hypothesized that PI3K pathway is as a major 
downstream of Tim-3. Akt inhibitor did not potently inhibited S6 phosphorylation upregulated 
by Tim-3 expression, while MEK inhibitor did. PDK1 could directly phosphorylate p70S6K at 
threonine in the activation loop and activated p70S6K [199, 200]. In CD8 T cells, deletion of 
PDK1 resulted in loss of S6 phosphorylation induced by IL-2 but treatment with Akti weakly 
inhibited S6K and S6 phosphorylation [201]. Moreover, Akt was dispensable for metabolism in 
CD8 T cells [201]. Thus, Tim-3 may be able to upregulated S6 phosphorylation via Akt-
independent pathway. To address this, I need to test the effect of PI3K or PDK inhibition in S6 
activation and investigate activation of p70S6K and p90S6K.  
Functionally, Tim-3 not only upregulated IL-2 production in Jurkat T cells, but also 
upregulated IFN-γ  production in primary murine T cells. Moreover, the consequence of T1 and 
T2 deletions of the cytosolic tail of Tim-3 on IFN-γ production were consistent with the results 
of NFAT/AP-1 and NF-κB reporter assays, indicating that Tim-3 exerts positive signaling that is 
not limited only to transformed T cell lines.   
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Figure 28. Model for acute enhancement of TCR signaling and activation by Tim-3 
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5.0  SUMMARY AND DISCUSSION 
We demonstrate that ectopic expression of Tim-3 upregulated NFAT/AP-1 reporter, NF-κB and 
NFAT reporter activity induced by TCR signaling and AP-1 activity independently of TCR 
stimulation. Tyrosine residues at 256 and 263 were required for the positive function of Tim-3 
and were available for phosphorylation. Tyrosine phosphorylation of Tim-3 was modestly 
induced by TCR stimulation. Then we searched for the signaling molecules interacting with the 
cytosolic tail of Tim-3. Through SH2 domain array we identified that proximal TCR signaling 
molecules like SFKs, p85 subunit of PI3 kinase, and PLC-γ1, and adaptor proteins involved in 
MAP kinase like Grb2, and GRAP.  Then, we confirmed Tim-3 interacts with Fyn and p85 PI3K 
in a tyrosinephosphorylation dependent and independent manner, respectively.  I revealed Tim-3 
expression enhances activation of PLC-γ1, MAP kinase, and S6, leading to IL-2 and IFN-γ 
production.  
Our data show that Tim-3 enhances, rather than represses, T cell activation, at least 
during short term stimulation (<6hr). Then, how does activation of T cell by Tim-3 mediate 
inhibition of T cell immune responses? One possibility is that Tim-3 may have both activating 
and inhibitory function, depending on the repertoire of the available ligands at the different stage 
of T cell differentiation. As discussed in Chapter 2.0 , Tim-3 may activate signaling by default, 
while association with certain ligands switches it to an inhibitory molecule. To-date, there are 
several ligands of Tim-3 identified, which alone may differentially influence T cells via different 
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affinity or different conformational change. BAT3 interacted with unphosphorylated Tim-3 
inhibiting negative regulatory function of Tim-3 [127]. Association of intracellular molecules in 
resting status may govern the default signaling in the absence of ligation.  
It is also possible that a combination of Tim-3 with signaling from other receptors 
determines the consequence of Tim-3 signaling in T cells. During chronic exhaustion of T cells, 
several exhaustion receptors are co-expressed with Tim-3, especially PD-1, so Tim-3 may 
cooperatively induce T cell dysfunction during T cell exhaustion. Indeed, T cell function was 
more severely impaired in Tim-3
+
PD-1
+
 T cells than in Tim-3
+
PD-1
-
 or Tim-3
-
PD-1
+
 cells, and 
co-blockade of Tim-3 and PD-1 was more efficient in restoration of T cell function than Tim-3 
or PD-1 blockade alone [47, 49, 115]. Given that the known Tim-3 ligands can interact with 
receptors other than Tim-3, the Tim-3 ligands may initiate Tim-3 independent signal or recruit 
other receptors to Tim-3. If so, the different combination of Tim-3 and non-Tim-3 signaling, or 
formation of different receptor complexes with Tim-3 may be able to differentially influence T 
cell function.  
Another possibility is that augmentation of T cell activation by Tim-3 eventually leads to 
inhibition of T cell function. First, Tim-3 may accelerate negative feedback. Above, I discussed 
Fyn as a putative molecule responsible for enhancement of TCR signaling. Intriguingly, Fyn also 
has role in negative regulation of TCR signaling. There were reported lymphoproliferative and 
autoimmune phenotypes in Fyn-deficient mice [202, 203] and Fyn is upregulated in anergic T 
cells [204]. PAG is a membrane adaptor protein which recruits Csk, an inhibitor of SFKs. Fyn 
interacts with PAG and phosphorylates PAG more efficiently than Lck to regulate the 
recruitment of Csk to PAG. In addition PAG associated Fyn enhances Ca
2+
signlaling, without 
MAPK activation leading to anergy induction in T cells [205-207].   
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Secondly, an activating signal by Tim-3 may contribute to induction or maintenance of T 
cell exhaustion. T cell exhaustion is the phenomenon whereby T cells lose their effector function 
over time, as T cells are chronically stimulated with persistent and high antigen load [208]. Gene 
expression array data show that of the genes differentially upregulated in exhausted CD8 T cells, 
a greater number of these genes overlap with effector T cells than with memory T cells. I looked 
up the expression profile of the candidate molecules of Tim-3 signaling in the gene array data 
[150]. Interestingly, activating molecules like Fyn, MAP3K1, and NFATc1 were upregulated 
and inhibitory molecules like RasGAP and Dgkα were downregulated, in the exhausted T cells. 
The observation that in chronic HIV patients, basal phosphorylation level of STAT5 and MAP 
kinases like ERK and p38 were elevated in Tim-3
hi
 CD8 T cells, compared to Tim-3
lo
 CD8 T 
cells  [115], also supports the correlation between hyperactivation of T cells and dysfunctional 
phenotype in Tim-3 expressing T cells. 
During immune activation as in infection, antigen-specific T cells initially expand and 
differentiate, then undergo contraction during which the activated effector T cells continue to 
differentiate to short-lived terminal effector or exhausted T cells and a subset of the effector cells 
become memory T cells [209]. At the level of single T cells, exhaustion is the loss of effector 
function and proliferative ability. In the scope of a T cell population, T cell exhaustion can be 
interpreted as depletion/loss of long-lived functional T cell population. Activating signal via 
antigen receptor is necessary for the differentiation of effector T cells and memory T cells during 
infection, there is evidence that strong activation, especially activation of metabolism pathway, 
skews the balance of T cell differentiation towards effector T cells, resulting in reduced memory 
T cell differentiation. Inhibition of mTOR with rapamycin during LCMV infection enhances the 
number and the quality of virus specific memory CD8 T cells [210],  prolonged IL-2R signaling 
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promoted terminal differentiation of effector CD8 T cells at the expense of memory CD8 T cells 
[211, 212]. In addition, there were drastic increases in the frequency of effector memory 
(CD44
hi
CD62L
lo
) CD4 T cells from Map3k2-/-Map3k3Lck-Cre/-CD4+ mice [213]. Interestingly these 
pathways overlap with the downstream signaling of Tim-3, that we identified.  
Thus, S6 is downstream of mTOR and MAP kinases pathway, ERK is downstream of 
MEKK2/MEKK3 and p85 is downstream of IL-2.  Analyzing the profile of activation and 
memory markers in Tim-3-PD-1
+
 and Tim-3
+
PD-1
+
 TILs, the frequency of CD44
int
 cells 
(transition from naïve to effector) and CD44
hi
CD62L
lo 
(effector memory) was similar and 
slightly higher, respectively, in Tim-3
+
PD-1
+
 TILs than Tim-3
-
PD-1
+
 TILs. However, the 
frequency of CD44
hi
CD62L
hi
cells (central memory) was much lower in Tim-3
+
PD-1
+
 cells [49]. 
Thus, I speculate that Tim-3 promotes T cell differentiation towards short-lived effector cells by 
contributing to stronger stimulation, resulting in loss of long-lived functional T cells.  
While we propose an acute activating function of Tim-3 in Th1 and CD8 T cells, PD-1 is 
known to inhibit the PI3K/Akt pathway, then how might Tim-3 and PD-1 cooperates in T cell 
exhaustion?  Recently, Macintyre et al demonstrated that IL-2-induced expression of CTL 
activation and metabolism were mediated by separate pathways. p110δ and Akt was necessary 
for the expression of CTL effector molecules like IFN-γ, perforins and granzymes, but 
dispensable for proliferation and metabolism in CD8 T cells. Instead, PDK1 is required for 
proliferation and metabolism by IL-2 [201].  Possibly, PD-1 inhibits the PI3K-Akt pathway to 
represses cytotoxic function of CD8 T cells, while Tim-3 activates metabolic pathways by 
activating ERK and S6, to promote T cell differentiation toward short-lived/exhausted T cells, at 
the expense of memory precursors (Figure 29). To address this issue, it will be very interesting to 
investigate whether Tim-3 modulates metabolism of effector T cells, and affects effector and 
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memory formation in chronic infection or tumor conditions using Tim-3 transgenic or knockout 
in vivo model.  
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Figure 29. Model for a role of Tim-3 in effector/memory T cell differentiation. 
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Part of this research and all or part of Figure 6, Figure 7, Figure 10, Figure 11, Figure 13, 
Figure 14, Figure 15, Figure 17, Figure 18, Figure 20, Figure 22, Figure 23, Figure 25 and Figure 
26 were originally published in Molecular and Cellular Biology.  Judong Lee, Ee Wern Su, Chen 
Zhu, Sarah Hainline, Jiayao Phuah, Jamie A. Moroco, Thomas E. Smithgall, Vijay K. Kuchroo 
and Lawrence P. Kane. Phosphotyrosine-Dependent Coupling of Tim-3 to TCR Signaling 
Pathways. Molecular and Cellular Biology. 2011, 31(19):3963-3974. © the American Society 
for Biochemistry and Molecular Biology. 
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APPENDIX A 
ABBREVIATIONS  
AML acute myeloid leukemia 
AP-1 activator protein 1 
BMMC bone marrow-derived mast cell  
CIA collagen-induced arthritis 
CRD carbohydrate recognition domain 
CTLA-4 cytotoxic T lymphocyte antigen 4 
DAG diacyl glycerol 
EAE  Experimental autoimmune encephalomyelitis 
HMGB1  high mobility group protein B1 
IP immunoprecipitation 
IP3  inositol 1,4,5-trisphosphate  
ITAM immunoreceptor tyrosine-based activation motif 
ITIM immunoreceptor tyrosine-based inhibitory motif 
ITSM immunoreceptor tyrosine-based switch motif 
LAT lymphocyte activting protein 
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LCMV  lymphocytic choriomeningitis virus 
MILIBS metal ion dependent ligand binding site  
MOG myelin oligodendrocyte glycoprotein 
MS multiple sclerosis 
mTOR mammalian target of rapamycin 
NF-κB nuclear factor kappa B 
NFAT nuclear factor of activated T cells 
NOD non-obese diabetic 
NSCLC non-small cell lung cancer 
PD-1 programmed death 1 
PDK 3'-phosphoinositide-dependent kinase 
PI3K phosphoinositol-3 kinase  
PIP2  Phosphatidylinositol 4,5-bisphosphate  
PLC phosphoalipase C 
PMA phorbol 12-myristate 13-acetate 
PMBC peripheral blood mononuclear cell 
PS phosphatidylserine 
RA rheumatoid arthritis 
SFK Src family kinae 
SLP-76 SH2 domain containing leukocyte protein of 76kDa 
TIL tumor infiltrating lymphocyte 
TIM T cell immunoglobulin and mucin domain protein 
ZAP70 zeta-chain-associated protein kinase of 70 kDa 
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